

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Current issues and Future considerations for the wider implementation of Robotic Assisted Surgery: A qualitative study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-067427
Article Type:	Original research
Date Submitted by the Author:	12-Aug-2022
Complete List of Authors:	<p>Lawrie, Louisa; University of Aberdeen, Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition</p> <p>Gillies, Katie; University of Aberdeen, Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition</p> <p>Davies, Loretta ; University of Oxford, RCS Surgical Interventional Trials Unit (SITU), Nuffield Dept Orthopaedics, Rheumatology and Musculoskeletal Sciences</p> <p>Torkington, Jared; University Hospital of Wales Healthcare NHS Trust, Department of Colorectal Surgery</p> <p>McGrath, John; Royal Devon and Exeter NHS Foundation Trust, Department of Urology</p> <p>Kerr, Richard; Royal Devon and Exeter Hospital, Department of Neurosurgery</p> <p>Immanuel, Arul; Newcastle Upon Tyne Hospitals NHS Trust, Northern Oesophago-Gastric Unit</p> <p>Campbell, Marion; University of Aberdeen, Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition</p> <p>Beard, David; University of Oxford, RCS Surgical Interventional Trials Unit (SITU), Nuffield Dept of Orthopaedics, Rheumatology and Musculoskeletal Sciences</p>
Keywords:	QUALITATIVE RESEARCH, SURGERY, HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Current issues and Future considerations for the wider implementation of**  
4  
5  
6 **Robotic Assisted Surgery: A qualitative study**  
7  
8

9 **Louisa Lawrie<sup>1\*</sup>, Katie Gillies<sup>1</sup>, Loretta Davies<sup>2</sup>, Jared Torkington<sup>3</sup>, John McGrath<sup>4</sup>**

11 **Richard Kerr<sup>5</sup>, Arul Immanuel<sup>6</sup>, Marion K Campbell<sup>1+</sup>, David J Beard<sup>2+</sup>**  
12  
13

14  
15 <sup>1</sup> Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical  
16 Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, UK.

17  
18  
19 <sup>2</sup> RCS Surgical Interventional Trials Unit (SITU), Nuffield Dept Orthopaedics, Rheumatology and  
20 Musculo-skeletal Sciences, University of Oxford, UK.  
21

22  
23  
24 <sup>3</sup> Department of Colorectal Surgery, University Hospital of Wales Healthcare NHS Trust, Heath Park,  
25 Cardiff, UK.  
26  
27

28  
29 <sup>4</sup> Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.  
30

31  
32 <sup>5</sup> Department of Neurosurgery at Oxford Radcliffe Hospitals NHS Trust, UK.  
33

34  
35 <sup>6</sup> Northern Oesophago-Gastric Unit, Newcastle Upon Tyne Hospitals NHS Trust, UK.  
36

37  
38 \* Corresponding author  
39

40  
41 + Joint senior authors  
42

43  
44 E-mail: [louisa.lawrie1@abdn.ac.uk](mailto:louisa.lawrie1@abdn.ac.uk)  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** The effective implementation of a fast-changing healthcare delivery innovation, such as Robotic Assisted Surgery (RAS) into a healthcare system, can be affected (both positively and negatively) by external contextual factors. As part of a wider project investigating ways to optimise the implementation of RAS, this qualitative study aimed to uncover current issues of RAS and predictions about the future of robotic surgery. We refer to 'current issues' as the topical and salient challenges and opportunities related to the introduction of RAS in the UK healthcare system, from the perspectives of key stakeholders involved in the delivery and implementation of RAS.

**Design:** Semi-structured interviews and focus groups were conducted. A thematic analysis was conducted to summarise salient issues that were articulated by participants.

**Participants:** The interview sample (n = 35) comprised surgeons, wider theatre staff and other relevant personnel involved in the introduction and delivery of RAS services across the UK, including service managers and policy-makers/commissioners. Two focus groups were also conducted with surgical trainees (n = 7) and the public/patients (n = 8), respectively.

**Results:** The results revealed a largely positive attitude towards the introduction of RAS technology and an expectation of continued rapid expansion. Areas perceived to be particularly pertinent and requiring ongoing attention were also highlighted, including the need to achieve improved quality control, expertise quantification and training issues, and the need to educate the public. Issues of centralisation, service organisation and equity of access were also emphasised.

**Conclusions:** Our study has highlighted a range of issues perceived to be particularly pertinent to the current and future provision of RAS which should be addressed. The areas outlined can

1  
2  
3 enable healthcare managers and surgeons to plan for the adoption and/or expansion of RAS  
4  
5 services.  
6  
7

8 **Keywords:** Robotic Assisted Surgery; Implementation of RAS; Qualitative Research; Health  
9  
10 Services.  
11  
12

13  
14 Word count: 5547  
15  
16

#### 17 Strengths and limitations of this study

- 18 • The research provided insights into specific areas of focus for surgeons and managers  
19 currently planning RAS adoption or expansion.
- 20 • Stakeholders from several specialties were sampled, as well as surgical trainees,  
21 patients/public and health service managers.
- 22 • The sample for interview comprised mostly of surgeons and was small (although in line  
23 with other qualitative studies).  
24  
25  
26  
27

## 31 INTRODUCTION

32  
33  
34 There is increasing global adoption of Robotic Assisted Surgery (RAS) as a result of the  
35 suggested benefits for ergonomics, surgical precision, enhanced tissue visibility, reduced  
36 requirement for surgical assistance, improved training and workflow practices(1–5). Further  
37 expansion of robotic surgical systems is also forecast(4,6,7). The implementation of RAS, as a  
38 relatively new technology and having substantial differences to existing surgical healthcare  
39 delivery, can be considered “disruptive” (it requires system change), and several areas of new  
40 knowledge may be required to facilitate widespread implementation(8,9). Furthermore, the  
41 introduction of fast changing technology can be susceptible to misinformation, sensationalism,  
42 and early adoption bias(10,11). It is therefore critical to obtain a balanced and representative  
43 picture of current issues that could potentially affect wider implementation or roll out. This  
44 information can help with decision making, inform evolving implementation plans and ongoing  
45 clinical pathway development, ultimately leading to better patient care.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This study was part of a wider project set up to formally explore the barriers and facilitators  
4 to the implementation/scale up of RAS services at different stages of the implementation  
5 process, focusing on both technology-specific and behavioural influences. The broad aim of  
6 this element was to uncover and report current issues of RAS and predictions about the future  
7 of robotic surgery. We refer to current issues as the topical and salient challenges and  
8 opportunities related to the introduction of RAS in the UK healthcare system, from the  
9 perspectives of key stakeholders involved in the delivery and implementation of RAS.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

## 23 **METHOD**

### 24 **Design**

25  
26 This was a qualitative study using semi-structured interviews and focus groups. The  
27 Consolidated Criteria for Reporting Qualitative Research was employed for the study  
28 report(12). This study was part of a wider project (13) examining the barriers and enablers to  
29 the implementation of RAS using approaches from behavioural and implementation science.  
30 The questions within the interview topic-guide (see online supplementary file 1) were primarily  
31 developed to examine the factors that affect the implementation of RAS from a behavioural  
32 and technology-specific perspective, but also included broader questions about general  
33 perceptions of RAS. The present study reports findings from the concurrent inductive analysis  
34 of the data regarding current contextual issues surrounding RAS.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 The present study also involved two focus groups with surgical trainees and the  
51 public/patients, respectively. Focus group questions were designed to gauge general  
52 perspectives in terms of participants' understanding of RAS (most notably for the  
53 patients/public), the advantages and disadvantages of RAS (relevant to both focus groups), the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 future of RAS and the consequences of RAS adoption on skills development (Surgical Trainees  
4 focus group).  
5  
6  
7

8 Initial key informant/pilot interviews were conducted to test the suitability of our interview  
9 topic guide. Interview guides were also adapted to ensure that the questions were relevant to  
10 each participant role (e.g. surgeons, nurses, and industry partners).  
11  
12  
13  
14  
15

## 16 **Participants**

### 17 **Semi-structured Interviews**

18  
19 The sample was purposively selected to contain surgeons, wider theatre staff and other relevant  
20 personnel involved in the introduction and delivery of RAS services across the UK, including  
21 service managers and policy-makers/commissioners. Participants were identified through  
22 clinical and research networks, such as the Royal College of Surgeons of England Robotic &  
23 Digital Research (RADAR) group, surgical research networks, industry connections and local  
24 hospital knowledge. A broad range of disciplines and representation was sought.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Focus Group: Surgical Trainees**

41  
42 Early career surgical trainees from various specialties were purposefully selected to  
43 complement the interview data - which mostly represented clinical viewpoints from established  
44 surgeons at later stages of their careers or other non-surgical staff. The trainee group were  
45 accessed and invited through National Surgical Trainee Collaboratives.  
46  
47  
48  
49  
50  
51

### 52 **Focus Group: Patients/Public**

53  
54  
55 A further focus group was held with patients and members of the public (linked to the Health  
56 Services Research Unit) to establish their perspectives about robotic assisted surgery, including  
57 the outcomes they thought were important to them when evaluating RAS.  
58  
59  
60



## Data Collection

Following piloting, interviews were conducted by LL8-, with observation and assistance by MC or DB. All interviews were conducted via Microsoft Teams(14). Data collection took place between October 2020 – March 2021. Interview transcripts were anonymised and subjected to the analysis process outlined below.

## Data Analysis

A thematic data-driven inductive approach to analysis(15) was adopted to explore wider contextual perspectives on current and potential future issues of RAS. Following review/refinement of themes, a thematic framework was developed (LL, reviewed by KG, MC, DB) which described the content of all themes with illustrative quotes to facilitate data analysis. Data analysis was supported through using NVivo(16) and Microsoft Excel(17).

## Statement of funder contribution

The funder had no role in the conception, design, conduct, analysis, or interpretation of the study.

## Patient and public involvement

None.

# RESULTS

## Demographics

Sample demographics are provided in Table 1. In total, 35 stakeholders were interviewed. Twenty-two clinical stakeholders (including surgeons, wider theatre staff and service managers) across a range of clinical specialties were sampled from a total of 16 National Health Service (NHS) hospital sites located across England, Scotland, and Wales.

Seven surgical trainees participated in the trainee focus group. Five trainees were sampled from five different UK hospital sites, two were from international institutions at the time of interview (but acquired previous clinical practice in the UK). Trainee specialties are summarised in Table 1. All trainees had experience of assisting in at least one robotic case, and two were undertaking robotic surgical fellowships.

Eight individuals participated in the patient/public group. Prior to the patient/public focus group, participants attended an information session led by a surgeon. This session was designed to introduce RAS, provide information regarding the conduct of RAS and acted as an opportunity for the public to ask questions. None of the participants reported having had a robotic assisted procedure, although some indicated their patient experience of other types of keyhole surgery.

Characteristic	Interviews	Trainee Focus Group
	<i>N</i> = 35	<i>N</i> = 7
<b>Age</b>		
Median	50	35.5
Range	30-70	31-37
<b>Gender</b>		
Female	7	4
Male	27	2
<b>Ethnicity</b>		
Asian British	3	-
Caucasian	29	5
Indian	1	-
Other white background	1	-
Chinese Asian	-	1
<b>Role</b>		
National Surgical Specialty Leader	5	-
Surgeon (RAS user)	11	-
Surgeon (Non-RAS user)	2	-
Scrub Nurse	2	-
Industry representative	5	-
Policy Commissioner	5	-
Surgical Trainee	2	7
Anaesthetist	1	-
Service Manager	2	-
<b>Specialty (Leaders, Surgeons, Trainees)</b>	<b><i>N</i> = 20</b>	

Urology	5	-
Colorectal	8	1
General	2	1
Orthopaedics	3	2
Gynaecology	1	1
Thoracic	1	2

**Table 1.** Demographic data for the interviewees and focus group (Trainee) participants. *Note:*

Age, gender, and ethnicity was not recorded for 1 interview participant and 1 focus group (Trainee) participant.

## Findings

Participants raised several key issues influencing the current provision and implementation of RAS in the NHS. The issues identified related to the evolution and future direction of RAS services, as well as issues that affect service implementation including workforce training, governance, and the potential for de-skilling. The impact of external influences, particularly public perceptions, was also highlighted. These are discussed in more detail below.

### Evolution and future direction of RAS

#### Rapid evolution of RAS

RAS was perceived to be evolving at a rapid pace in terms of both widespread adoption and robotic technological advancements. Some participants positively highlighted the need for healthcare systems to embrace this evolutionary process:

“...As robotics are evolving, the NHS needs to be involved because the surgeons and clinicians and all NHS staff would be left behind if they weren’t involved now.” Industry stakeholder, P2I26.

1  
2  
3 However, others emphasised the need for the wider system and evaluation (evidence) to catch  
4 up to allow a more joined-up roll-out going forward. Some noted that the rapid uptake of RAS  
5 meant that evaluative studies investigating the technology often lagged behind the adoption:  
6  
7

8  
9  
10 “... so I think that’s where the big data, where the registries and where the collaborative multi-centre  
11 cohort studies data will be very useful....by the time you get level one data it will have moved on...,  
12  
13 people would have learned the technology, they would have believed in it and they would have  
14  
15 [already] moved on to the next thing.” RAS Surgeon, P11S.  
16  
17

18  
19  
20 However, participants also acknowledged the challenges associated with conducting  
21 meaningful evaluation alongside rapid roll-out, particularly in learning curve phases but also  
22 when clinician equipoise might be evolving or where patient preference is strong:  
23  
24

25  
26  
27 “....you will have more robotic surgeons who are experienced, trained and on the learning curve...  
28  
29 over the learning curve they’ll find it difficult to recruit patients into the laparoscopic arm of the  
30  
31 study.” RAS Surgeon, P12S.  
32  
33

34  
35 The need to demonstrate the benefits of RAS, particularly longitudinally and those that are  
36 not immediately visible was stressed. Whilst this is not unique to RAS, it was acknowledged  
37 that good cost-effectiveness data would aid the greater implementation of RAS:  
38  
39

40  
41  
42 “It’s quite important I think to actually quantify this benefit economically.... So it’s not just the  
43  
44 length of stay in hospital, it’s also their return of function in the community and it’s the lesser  
45  
46 or the sparing of community resources.” RAS Surgeon, P11S.  
47  
48  
49  
50

## 51 Future direction of RAS

52  
53  
54 There was widespread perception that robotic assisted surgery is “here to stay” and will be  
55  
56 more commonplace in the future. A minority of interviewees felt RAS might be something of  
57  
58  
59  
60

1  
2  
3 a fad that may go out of fashion. Overall, there was a perception that progress was strongly  
4  
5 linked to the ongoing routine digitisation and technological advance in healthcare:  
6  
7

8 “Everything has a screen on it now. Everything is digitised. We’re going down that path.” Scrub  
9  
10 Nurse, P12N  
11

12  
13 “So yes, definitely evidence is a big part of that, but we all know we also need to see advances in  
14  
15 the technology. But the advances in the technology will come as the robots become used more.”  
16

17  
18 Specialty Leader, P2S21  
19

20  
21 However, there were some concerns that COVID-19 might negatively influence the provision  
22  
23 of RAS in the future, due to the financial constraints within the NHS exacerbated by the  
24  
25 pandemic:  
26

27  
28 “I do worry a little bit that constraints over the next two or three years are going to be quite daunting  
29  
30 in terms of I think money [for RAS] is going to be tight and it is tight within the NHS... whether  
31  
32 that’s with COVID or I don’t know.” Scrub Nurse, P12N.  
33

34  
35 Clinical participants provided insights on the dynamic nature of the RAS market, including  
36  
37 perceptions on how RAS might evolve. Some participants indicated that surgical robots would  
38  
39 likely become more autonomous in the future. There were also comments related to the  
40  
41 potential of RAS to be conducted by surgeons who are located overseas/physically distant from  
42  
43 the theatre:  
44

45  
46  
47 “So I could be in my office now doing work but one of my team could be in trouble in the  
48  
49 operation and they could literally just log on to the computer and show me what they’re doing and  
50  
51 I could say, “Okay, I’ll take over the controls and I’ll just fix that”.” Specialty Leader, P2S21.  
52

53  
54 One industry stakeholder indicated that surgeons may become more comfortable with the  
55  
56 prospect of receiving virtual expert RAS guidance/assistance due to remote care becoming  
57  
58 more commonplace during the COVID-19 pandemic:  
59  
60

1  
2  
3 “...we’ve learnt a lot about how you can be more in places at once ...so I think Covid is helping us  
4 through that. I think a surgeon is going to be much more comfortable getting expert advice from  
5 somebody that’s nowhere even near them..” Industry representative, P2I24.  
6  
7  
8  
9

10 However, some participants from the patient/public focus group expressed concerns about  
11 the possibility of a more remote model of care, indicating that they would feel more  
12 comfortable in the presence of a surgeon during the entirety of a RAS procedure:  
13  
14  
15

16  
17  
18 “I think I’d want to be reassured that there was going to be a surgeon or any other kind of doctor  
19 there permanently throughout the entire operation in case something went south.” Participant 5,  
20 patient/public focus group.  
21  
22  
23

24 Many clinical participants indicated that the capital cost of RAS is expected to decrease, and  
25 some linked this to the potential introduction of new companies to the market:  
26  
27  
28

29  
30 “I think the instruments, the prototypes, the equipment is going to evolve, it’s going to continue to  
31 change, it’s going to be more powerful, it’s going to be more intelligent, it’s going to be less  
32 expensive.” Specialty Leader, P01S.  
33  
34  
35

36  
37 “I can only see at some stage ... the cost will come down further and is coming down because there’s  
38 more competition in the market.” Scrub Nurse, P12N.  
39  
40  
41  
42  
43  
44

## 45 Role of industry

46  
47 There were mixed views on the role and involvement of industry within current and future RAS  
48 service provision. Many participants indicated the positive opportunities that could arise from  
49 a collaborative relationship with industry, citing that the UK does not often embrace industry-  
50 led partnerships and perhaps should. The capability of industry to facilitate training, utilise  
51 better resources and form more of a collaborative approach to development was expressed by  
52 trainees:  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 “Industry is traditionally almost a dirty word in surgery and even more with surgical academics.  
4  
5 However, like many things I believe we are historically behind our European and US colleagues in  
6  
7 our involvement with industry.” Participant 7 Focus group Surgical Trainee.  
8  
9

10 Some participants, however, voiced a wish for greater independence in regard to issues such  
11  
12 as RAS training in the future and wished to have more control of the strategy:  
13  
14

15 “...I think we need to...seriously think about taking control of our own training in robotics or at  
16  
17 least having more of a role in collaborating with industry.” Participant 6 Focus group Surgical  
18  
19 Trainee.  
20  
21

22 Particular concerns regarding market dominance were also expressed:  
23  
24

25 “....The problem is a lot of robotic proponents are now employed by industry to become their  
26  
27 proctors or key opinion leaders and that then becomes very awkward... I think right now, robotic  
28  
29 surgery is industry driven, but I think we need to change that. And I think once we change that,  
30  
31 you’ll see a huge upscaling.” Surgical Trainee (Interviewee), P2S17.  
32  
33  
34  
35  
36

37 Acknowledging that RAS was likely to be part of the NHS for some time to come,  
38  
39 stakeholders raised a number of further points for discussion – as discussed below.  
40  
41

### 42 **The need for guidance, governance, regulation, and quality control**

43  
44

45 While RAS was acknowledged to be evolving at a rapid pace, clinical participants expressed  
46  
47 the need for national guidance to support adoption and future expansion. Many suggested a  
48  
49 national framework to support implementation, including training standards would be  
50  
51 beneficial. Relatedly, many participants verbalised support for national regulatory mechanisms  
52  
53 in place to ensure appropriate delineation of surgical responsibilities to avoid potentially  
54  
55 problematic situations arising:  
56  
57  
58  
59  
60

1  
2  
3 “So my concern.... is the worry that if things do not go according to the plan it’s very easy to blame  
4 the technology.... We have seen that with certain technologies ... and surgeons start to blame the  
5 equipment and the technique. So just there has to be some governance around the introduction and  
6 sudden...explosive expansion of that technology.” RAS Surgeon, P12S.  
7  
8  
9

10  
11  
12 “You could imagine .....if something were to go wrong in that [RAS] situation then that would cause  
13 a huge stir and would have a negative effect on ....trainees, certainly surgeons, and the public’s  
14 perception of robotic surgery”. Surgical Trainee (Interviewee) P2S12.  
15  
16  
17  
18

19 The capability of RAS to automatically generate accurate and substantial mechanical and  
20 outcome data was seen as a strong positive and of significant benefit for training, quality  
21 assurance and accreditation purposes. The versatility of RAS and its incorporation with other  
22 technological advances (Artificial Intelligence (AI), machine learning, big data) further  
23 strengthened this position:  
24  
25  
26  
27  
28  
29

30  
31 “I think first of all you can train your surgical workforce better...It allows you to use new tools i.e.  
32 augmented reality, mixed reality, simulation and robotics and use data for transition from one state  
33 to another and currently we don’t have. So data will also help us train our workforce differently and  
34 more effectively, that’s number one...” RAS Surgeon, P15S.  
35  
36  
37  
38  
39

40 However, the acceptability of standard data collection/monitoring facilitated by RAS within  
41 theatre practices still needs debate such that it would not be seen as a somewhat a “Big Brother”  
42 development which could be misused:  
43  
44  
45  
46  
47

48 “...[some] people .. wouldn’t necessarily want that...level of monitoring like you have in the black  
49 box in an aircraft is not appropriate for surgery. I think that’s an ongoing debate that needs to be  
50 addressed... it kind of introduces a Big Brother culture of what goes on in an operating theatre, a  
51 previously sacred environment, and essentially it’s eavesdropping on that.” Industry representative,  
52  
53  
54  
55  
56 P03I.  
57  
58  
59  
60



## Workforce issues - training to support RAS and future potential for deskilling

### Workforce training needs

In addition to the need for increased governance, there was also a perceived ongoing need to adapt the capacity and structure of NHS training for RAS to optimise readiness for further RAS expansion among the workforce. Both surgeons and trainees mentioned the imperative to be able to achieve minimal competence and overcoming the learning curve, especially whilst RAS surgery is not the norm within the NHS for most surgical specialties. Whilst outside specialist training centres provide support, there was a suggestion that RAS surgery training may be in its infancy and required expansion. There was the perception that experienced surgeons are more easily accommodated in the RAS training setting currently, but that trainees should also be catered for.

### Potential for workforce deskilling

Participants also highlighted the potential that the expansion of RAS may result in deskilling the workforce in other surgical approaches (especially open surgery) in the future – as was seen with the roll out of other minimally invasive surgery. Widespread adoption of RAS may limit exposure to, and create diminished skills of, open surgery or non-RAS endoscopic surgery amongst the surgical community:

“There may be a loss of an open skill set and obviously trainees aren’t getting as much hands on during cases if they don’t have the basic robotic training done.” Focus group Surgical Trainee, Participant 6.

However, this was countered by others who reported that performing minimally invasive procedures, in which RAS is embedded, enhanced overall surgical capability and proficiency. In such a case the emphasis is on upskilling, rather than deskilling:

1  
2  
3 “...the reality is laparoscopic surgery is actually technically more challenging than open surgery.  
4  
5 You have to have, in a way, a better understanding, or at least the same understanding, of the  
6  
7 anatomy, and I don’t know any good laparoscopic surgeons who aren’t good open surgeons as well.”  
8

9 RAS Surgeon, P2S11.  
10  
11  
12  
13  
14

### 15 **Service design issues: centralisation, and equity of access**

#### 16 17 18 Centralisation or distributed services

19  
20  
21 Some participants held strong views about the concept of centralisation: the idea that RAS  
22  
23 should be delivered by specialist centres in specific regions of the UK. Proponents of  
24  
25 centralisation cited that any fragmentation of RAS services could be detrimental because of the  
26  
27 low case volumes of individual surgeons and a subsequent lack of quality control. They also  
28  
29 argued that centralisation is a preferred model because of the team approach requirement:  
30  
31

32  
33 “...I think you need to centralise this practice [RAS], you need to invest more robotic platforms in  
34  
35 selected hospitals.” RAS Surgeon, P12S.  
36  
37

38  
39 There was variability in the perception of suitability for centralisation for different specialties.  
40  
41 One participant highlighted the value of centralisation in relation to RAS Urology services in  
42  
43 the UK specifically, but expressed concerns regarding the practicalities of centralising practices  
44  
45 for other specialties. They also highlighted the complexities associated with the fragmented  
46  
47 development of multi-specialty RAS services across the UK.  
48  
49

50  
51 In line with the arguments for centralisation, some participants compared the organisation of  
52  
53 services in the UK and US, suggesting that centralisation of RAS practices can be an ideal  
54  
55 method of maximising surgical volume with resultant positive clinical outcomes:  
56  
57

58  
59 “I would like to see the complex surgeries done in centres of excellence by teams, not by individuals,  
60  
and moving through high volumes...” Industry stakeholder, P2I13.

1  
2  
3 Relatedly, participants verbalised their views around the likely or ideal configuration of RAS  
4 service provision in the future. Some participants drew upon their observations of surgical care  
5 during COVID-19, indicating that the lessons garnered from using mixed models of service  
6 delivery in the UK could be applied to RAS:  
7  
8  
9  
10  
11

12  
13 “I think one of the things COVID has shown us that the way our model of mixing up emergency  
14 care and elective care has caused significant harm to people who didn’t have COVID sadly and that  
15 will die of other reasons i.e. cancer not being treated and other things. I’d even look at models [of  
16 RAS] with elective care is separate from emergency care.” Specialty Leader, P15S.  
17  
18  
19  
20  
21  
22

#### 23 24 25 Equity of access

26  
27  
28 There were also concerns about the current set up of RAS and the need for equity of access for  
29 the population to the best interventions:  
30  
31

32  
33 “... there is a strong correlation between the poorer parts of the UK and the lack of access to any  
34 minimally invasive surgery, and then following on from that, robotic surgery...” Industry  
35 representative, P03I.  
36  
37  
38  
39

40 This theme was also highlighted by commissioners who stressed the need to make the strategy  
41 for expanding RAS services across certain areas of the UK, equitable:  
42  
43

44  
45 “... a big problem in [one region of the UK], we have huge inequalities, and if it ends up that the  
46 middle-class get the robot and the rest get the other... down the road, well that’s not so good, is it?  
47 ... Again, we don’t want to create more inequalities.” Policy-maker/commissioner, P2SM20.  
48  
49  
50  
51

52 In contrast, some also suggested that RAS can provide equitable surgery and improve patient  
53 access to minimally invasive surgery:  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 “You could argue that if it [RAS] increases access to minimally invasive surgery, then that could fit  
4 in with that ethos of levelling things up, of providing equitable surgery that the best surgery to  
5 everyone. I think the difficulty is always going to be around the initial cost” Specialty Leader, P01S.  
6  
7  
8  
9

### 10 11 12 13 **Need for improved Public Understanding** 14

15  
16 As well as perceived challenges associated with the NHS accommodating service and training  
17 issues, the interviews and focus groups highlighted the lack of public understanding of RAS  
18 and the importance of educating the public about what to expect from RAS:  
19  
20  
21

22  
23 “...there’s a real patient expectation problem sometimes, where people felt it was going to be  
24 magical... it’s a common one... the ‘sparkle dust’ problem. People think it’s new and it’s going to  
25 have no problems.” Surgeon (non-RAS user), P2S6.  
26  
27  
28

29  
30 “So at the moment there’s a complete misunderstanding around robotics, and what it is. If you say  
31 to a patient, what’s their perception of it...not in a medical context, they think about big machines  
32 putting cars together in factories and Amazon packaging up parcels. As a result, artificial intelligence  
33 and robotics terminology has become mixed, and the perception of a robot is for surgery is actually  
34 largely around artificial intelligence. When you then talk through the fact that there’s a surgeon  
35 involved all the time, they’re connected, they’re in the operating theatre, a lot of the fears and things  
36 start to disappear. But the problem is, you have to have that conversation at an individual level at  
37 the moment. There’s not that common awareness that a robot that’s used for surgery is very different  
38 to a robot that, for instance, is used to assemble a car.” Industry representative, P03I.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 Participants in the public focus group indicated a need for greater information and  
51 understanding around RAS terminology, to avoid further misconceptions about what robotic  
52 (assisted) surgery actually entails, particularly to address misconceptions about issues such as  
53 the level of autonomy afforded to the surgeon and how dominated it is by independent AI  
54 technology. There was little true understanding of the “tool” aspect of RAS and the primary  
55  
56  
57  
58  
59  
60

control/replication model:

“...I would be very keen to know what degree of control the doctor has, because whether you call it robotic assisted or robotic, the term “robot” is there, and if there’s a bit at the end saying “assisted” it’s not hugely relevant I think if you were quite fearful about going into surgery. So for me I would really want to know that there was (a) going to be a doctor present, ...there’s no indication that if it’s robotic surgery that there will be, and also to know that it is still the doctor who’s in charge. So I think, I mean I think that point about language is a really significant one.” Public/patient focus group participant 7.

However, public focus group participants also highlighted the importance of continuing to place trust in the Surgeon, regardless of the surgical method deployed. In terms of benefit, many clinical and industry stakeholders highlighted the notion that the public often perceive RAS in a disproportionately positive manner, often equating advanced technology with superior care. There were suggestions that there may be some value in educating the public to ensure appropriate expectations of RAS, especially in any roll out period. The undue influence of media was also highlighted, reinforcing the need for accurate public information to be developed and disseminated:

“there was a huge media thing around it [a famous person getting robotic surgery]. Because they were treated robotically, there was a very large uptake in patients going to hospitals or going through screening, and so suddenly it went up.” Industry representative, P03I.

## DISCUSSION

This study derived from a broad sample of high engagement RAS personnel, highlighted a range of issues particularly pertinent to the current provision of RAS and to future service needs which require more urgent consideration.

1  
2  
3 The rapid evolution of RAS for an institution such as the NHS was largely welcomed but  
4  
5 offset with the need to ensure that training capacity and patient education kept up in parallel.  
6  
7 Such reservation was highlighted further by an expressed wish for greater evidence  
8  
9 (effectiveness and cost effectiveness) to support more rapid adoption. It was reported that the  
10  
11 escalating uptake of RAS meant that evaluative studies often lagged behind the adoption, an  
12  
13 all too familiar phenomenon in healthcare delivery(11,18,19). There was a perception that  
14  
15 much of the rapid development was somewhat fiscally driven, rather than driven by high  
16  
17 quality evaluative evidence. This imbalance will need addressing, and likely quickly, to help  
18  
19 commissioners make informed decisions about investment in RAS for the longer term.  
20  
21  
22  
23

24  
25 There was a clear perceived need for improved guidance, governance, and regulation. As  
26  
27 articulated by some interviewees, the roll out at present is not supported by a national  
28  
29 framework (in the UK) and, whilst a “light touch” approach can have many positives, it was  
30  
31 clear that a governance framework would help should anything “go wrong”. The safety  
32  
33 reassurance offered at present, especially from a central governance perspective, was not seen  
34  
35 to be effective enough.  
36  
37  
38

39  
40 The surgical training aspect was another area of comment, especially from the trainee group.  
41  
42 Achieving competence and experience of RAS using RAS platforms is very different to  
43  
44 standard surgical training. There are currently capacity issues which limit opportunities to train  
45  
46 on RAS systems – especially as the entire workforce requires training. Also, as with other  
47  
48 minimally invasive approaches, becoming accredited in RAS for a procedure may reduce  
49  
50 exposure of a trainee surgeon to non-RAS experience and competence. In contrast, the ability  
51  
52 to quantify expertise and skill was seen as a strong positive feature for RAS. Both for trainees  
53  
54 and experienced surgeons learning a new surgical method, the ability to gauge and grade  
55  
56 competency in a much more quantitative way was welcomed. The need to adapt training to the  
57  
58 changing needs for surgical trainees has been identified in the recent report commissioned by  
59  
60

1  
2  
3 the Royal college of Surgeons (England)(7).  
4  
5

6 There were mixed views on whether centralisation of RAS services should become the model  
7  
8 of choice within the health service. However, there was a strong wish that the way in which  
9  
10 RAS should be rolled out should promote equity of access to treatment. RAS systems are scarce  
11  
12 high value commodities, and currently more difficult to access for some than standard surgery.  
13  
14 Centralisation has been shown to be highly effective for other areas of high-end health care  
15  
16 provision such as specialist major trauma care(20), but this requires further research for the  
17  
18 field of RAS.  
19  
20  
21  
22

23 The role of industry figured prominently in the interviews, both positively and sometimes less  
24  
25 so. The main conflict was around perceptions of partiality and market dominance. A  
26  
27 collaborative relationship with an energised and interested industry partner was thought to  
28  
29 bring many benefits (as has been seen with this research project). Training, facilitation,  
30  
31 information sharing and research opportunities/funding were all seen as positive contributions  
32  
33 to RAS development. The perceived influence of industry in the RAS sphere was a concern  
34  
35 voiced by some, especially outside the private sector. However, even in the limited time since  
36  
37 data collection for this report, significant improvements have occurred with industry bodies  
38  
39 providing a strong and united voice through institutions such as the Association of British  
40  
41 HealthTech Industries (ABHI) and support of independent research.  
42  
43  
44  
45

46 There is a clear need for wider education amongst the public. The public often perceive RAS  
47  
48 in a potentially disproportionately positive manner, often naively equating advanced  
49  
50 technology (RAS or otherwise) with superior care – there is an assumption that because it is  
51  
52 new, it is automatically good. Patients also found it difficult to discern the levels of autonomy  
53  
54 involved with RAS. Some respondents assumed a lack of surgeon input, highlighting  
55  
56 misconceptions of current RAS systems where the surgeon remains in total control of both  
57  
58  
59  
60

1  
2  
3 movement and decision making. The “trust” in the surgeon is, and remains, paramount. Future  
4  
5 positioning of RAS, in terms of autonomy and technical hierarchy, and good descriptions of  
6  
7 these for public education, are required. Platforms which aim to inform patients and public,  
8  
9 such as Healthtalk.org, may be useful in this regard.  
10  
11  
12  
13  
14  
15

### 16 **Strengths and Limitations**

17  
18  
19 Strengths of the study included the level of engagement and representation from a significant  
20  
21 body of RAS related experts and personnel, including open and deep insights gained from  
22  
23 industry and hospital managers. There were some limitations to the study. The sample for  
24  
25 interview comprised mostly of surgeons and was small (although in line with most qualitative  
26  
27 studies). There were dedicated focus groups to ensure surgical trainees and patient/public  
28  
29 perspectives were also represented but the surgeon voice was prevalent. We attempted to  
30  
31 sample multiple specialties to counter criticisms of other qualitative studies which only focus  
32  
33 on a single specialty(21). We also aimed to recruit multiple stakeholders.  
34  
35  
36  
37

38 Although we deliberately invited interviewees that were both known to be more or less  
39  
40 positive about RAS for balance, the natural sampling resulted in a preponderance of persons  
41  
42 who were RAS supporters. This is worthy of further comment. The identification of any  
43  
44 potential issues and problems with RAS outlined in this study has originated from those who  
45  
46 are, in general, users of RAS and largely supportive, and who have substantial direct insight.  
47  
48 As such, by amplifying the elements of RAS implementation that they have deemed to work  
49  
50 well and by addressing early the elements that they believe still require refinement will likely  
51  
52 head off any more troublesome aspects around future development. Sharing these insights and  
53  
54 thoughts will further this ambition and allow the best possible environment for appropriate roll  
55  
56 out of RAS.  
57  
58  
59  
60



## Conclusions

Our study demonstrated a largely positive attitude towards the introduction of RAS and an expectation of continued rapid roll out. It highlighted a range of issues which stakeholders perceive to be particularly pertinent to the provision of RAS which require greater attention. These included issues of governance, workforce training, organisation delivery and a continuing need for public education. These provide useful areas of focus for healthcare managers and surgeons currently planning the adoption or future expansion of RAS services.

**Acknowledgments:** We thank the participants for their time, energy, and invaluable insight to assist this research. Thanks to Clare Robertson for facilitating the patient focus group.

**Contributors:** MKC, DB and KG conceived the study. LL, DB, MKC, KG, LD, and CR (acknowledged) undertook data collection. LL, LD and KG conducted the data analysis. LL, DB, MKC, KG and LD interpreted the data. LL, DB and MKC drafted the manuscript and circulated to authors for contribution. LL, KG, LD, JT, JM, RK, AI, MKC and DB edited drafts and approved the current manuscript for publication.

**Funding:** This work was supported by Intuitive Surgical (European Research Board) via an unrestricted grant.

**Competing interests:** None declared.

**Patient and public involvement:** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication:** Not applicable

**Ethics approval:** This study was approved by the Life Sciences and Medicine Ethics Review Board (CERB) at the University of Aberdeen (CERB/2020/7/1984). Verbal informed consent was obtained from all participants.

**Data availability statement:** All data relevant to the study are included in the article.

## REFERENCES

1. Mcleod IK, Melder PC. Da Vinci robot-assisted excision of a vallecular cyst: A case report. *ENT-Ear, Nose & Throat Journal*. 2005;170–2.
2. Moawad GN, Rahman S, Martino MA, Klebanoff JS. Robotic surgery during the COVID pandemic: why now and why for the future. *Journal of Robotic Surgery*. 2020 Dec 1;14(6):917–20.
3. Ng ATL, Tam PC. Current status of robot-assisted surgery. Vol. 20, *Hong Kong Medical Journal*. Hong Kong Academy of Medicine Press; 2014. p. 241–50.
4. Matsuyama T, Kinugasa Y, Nakajima Y, Kojima K. Robotic-assisted surgery for rectal cancer: Current state and future perspective. Vol. 2, *Annals of Gastroenterological Surgery*. Wiley-Blackwell Publishing Ltd; 2018. p. 406–12.
5. Chan F. Robotic-assisted surgical procedures are the future of gynaecology in Australasia. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 2018 Jun 1;58(3):371–4.
6. Brodie A, Vasdev N. The future of robotic surgery. *Ann R Coll Surg Engl*. 2018 Sep 1;100:4–13.
7. Royal College of Surgeons. Future of Surgery [Internet]. [cited 2021 Jun 1]. Available from: [futureofsurgery.rcseng.ac.uk](http://futureofsurgery.rcseng.ac.uk)

- 1  
2  
3 8. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering  
4  
5 implementation of health services research findings into practice: A consolidated  
6  
7 framework for advancing implementation science. *Implementation Science*. 2009;4(1).  
8  
9
- 10  
11 9. Arroyo NA, Gessert T, Hitchcock M, Tao M, Smith CD, Greenberg C, et al. What  
12  
13 Promotes Surgeon Practice Change? A Scoping Review of Innovation Adoption in  
14  
15 Surgical Practice. Vol. 273, *Annals of surgery*. NLM (Medline); 2021. p. 474–82.  
16  
17
- 18  
19 10. Rogers EM. Diffusion of innovations. New York: NY: The Free Press; 1995.  
20
- 21  
22 11. Paul S, McCulloch P, Sedrakyan A. Robotic surgery: Revisiting “no innovation  
23  
24 without evaluation.” Vol. 346, *BMJ (Online)*. 2013.  
25
- 26  
27 12. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research  
28  
29 (COREQ): a 32-item checklist for interviews and focus groups. *International Journal*  
30  
31 *for Quality in Health Care*. 2007 Sep 16;19(6):349–57.  
32  
33
- 34  
35 13. Lawrie L, Gillies K, Duncan E, Davies L, Beard. D, Campbell M. Barriers and  
36  
37 enablers to the effective implementation of robotic assisted surgery.  
38
- 39  
40 14. Microsoft Corporation. Microsoft Teams. Redmond, Washington : One Microsoft  
41  
42 Way.  
43
- 44  
45 15. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in*  
46  
47 *Psychology*. 2006;3(2):77–101.  
48
- 49  
50 16. Jackson K, Bazeley P. Qualitative Data Analysis with NVivo. 3rd Edition. Sage  
51  
52 Publications; 2019.  
53
- 54  
55 17. Microsoft Corporation. Microsoft Excel. Redmond, Washington.  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
18. Collins R. Comment Metal-on-metal failures-in science, regulation, and policy. *The Lancet* [Internet]. 2012;379:1174–6. Available from: <http://www.ukbiobank.ac.uk/wp-content/>
  19. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al. No surgical innovation without evaluation: the IDEAL recommendations. Vol. 374, *The Lancet*. Elsevier B.V.; 2009. p. 1105–12.
  20. Metcalfe D, Bouamra O, Parsons NR, Aletrari MO, Lecky FE, Costa ML. Effect of regional trauma centralization on volume, injury severity and outcomes of injured patients admitted to trauma centres. *British Journal of Surgery*. 2014;101(8):959–64.
  21. Randell R, Honey S, Hindmarsh J, Alvarado N, Greenhalgh J, Pearman A, et al. A realist process evaluation of robot-assisted surgery: integration into routine practice and impacts on communication, collaboration and decision-making. *Health Services and Delivery Research*. 2017 Jun;5(20):1–140.



## Interview topic guide

Thank you for agreeing to participate in this interview. The general aim of the study is to help us understand more about the uptake of RAS. We are interested to hear what you think are the barriers and facilitators to introducing/scaling up RAS in the NHS and what issues are important to you in relation to RAS services. I have a number of questions I'm going to ask you – some questions may be more relevant to you depending on your role. We are interested in your experiences and views so there are no right or wrong answers. All information collected will be strictly confidential. Our chat today will be recorded. The audio recordings will only be used for transcribing and analysing data.

How does that sound?

Do you have any questions for me before we start?

Do I have your consent to get started?

Before we begin talking specifically about RAS, I would like to get some background information about yourself:

**What is your age?**

**Please indicate your gender.**

**What is your ethnicity?**

Question (background Qs designed to elicit RAS experience to date)	Probe(s)
1. What is your current role?	
2. Can you please start by explaining how familiar you are with RAS and your current level of expertise on the topic?	At what point did you or your team decide to use RAS and for what reason? [CFIR Planning <sup>1</sup> ] [if they have experience] How many years of experience do you have with (using) RAS? [surgeons] How many RAS procedures have you conducted?
3. [If no experience to date]: Do you wish to adopt RAS?	Why or why not?

<sup>1</sup> Consolidated Framework for Implementation Research (CFIR)  
Version 1.0 23/07/2020



## Interview topic guide

4. [If no experience to date]: Have you experienced any issues with the uptake of RAS in the past?		What happened?
<b>Target framework domain/construct</b>	<b>Question (specific Qs related to perspectives of RAS)</b>	<b>Probe(s)</b>
CFIR Evidence of strength and quality, TDF <sup>2</sup> Knowledge	5. Can you comment on the evidence related to RAS?	Evidence from your own research? Practice guidelines? Published literature? Co-workers? Other settings? What do you think of the evidence?
TDF Skills	6. What range of skills do you think are required to deliver RAS effectively?	Both in terms of technical skills to deliver RAS but also leadership, management, tendency towards innovation, agility  What type of training would be helpful?
TDF Beliefs about Consequences	7. In your opinion, what are the benefits of delivering RAS within the NHS?	To yourself, to the patients, colleagues, healthcare organisation, NHS – positive and negative, long/short-term. What about the benefits of not delivering RAS?
TDF Beliefs about Consequences	8. What are the drawbacks of introducing RAS in the NHS?	To yourself, to the patients, colleagues, healthcare organisation, NHS – positive and negative, long/short-term. What about the drawbacks of not introducing RAS to your organisation?
TDF Intentions and Goals, CFIR Other Personal Attributes	9. Can you describe what motivators are there for you personally in delivering RAS?	Has this changed since the introduction of RAS? If yes, what changed your motivation?

<sup>2</sup> Theoretical Domains Framework



Interview topic guide

<p>CFIR – relative advantage, TDF Goals</p>	<p>10. To what extent do you think that RAS should be a priority for the NHS at the moment?</p>	
<p>CFIR Tension for change, Patient needs and resources</p>	<p>11. Do you think it is really important to have a RAS service in your hospital? Why?</p>	<p>Is it worth it in terms of typical patient demographics, resources required?</p>
<p>TDF Environmental Context and Resources, CFIR Intervention Source, CFIR Structural Characteristics</p>	<p>12. [If RAS already implemented] Again, talking about your specific hospital, has it been relatively easy or difficult to implement RAS? Why?</p> <p>13. [If not implemented already] What is it about your hospital that would make it easier or more difficult to implement RAS in your hospital?</p> <p>14. How does your role/standing in the hospital influence how easy it is/would be to implement RAS?</p>	<p>Resource issues, organisational regulations, equipment, colleagues, the infrastructure of your organisation - social architecture (e.g. roles, hierarchy), age, maturity, size, or physical layout – how does this affect (or will affect) the provision of RAS?</p>
<p>CFIR External Policies and Incentives</p>	<p>[If RAS already implemented]</p> <p>15. Have any external policies or recommendations influenced the decision to implement RAS locally?</p>	<p>Give examples</p>
<p>CFIR Culture, TDF Social Influences, CFIR Peer Pressure,</p>	<p>16. To what extent have the views of others or what you have seen happening in other hospitals affect your uptake of RAS?</p>	<p>Do you think their opinions (would) influence the uptake of RAS? How do you think your organisation's culture (general beliefs, values, assumptions that people embrace) will affect (or does affect) the provision of RAS? Can</p>



## Interview topic guide

<p>CFIR Readiness for Implementation – Leadership Engagement</p>	<p>17. Thinking of other hospitals, in your view, who are the winners and who are the losers in the uptake of RAS?</p> <p>18. How open is your hospital to introducing new innovations like RAS?</p>	<p>you describe an example that highlights this? Example: any generational differences in opinions of RAS? Has this affected your views of RAS?</p>
<p>CFIR Patient Needs &amp; Resources/Peer Pressure</p>	<p>19. How do you think patients will (or do) respond to the introduction of RAS in your hospital?</p>	<p>Do you know how patients have responded to RAS in the past? Do you think RAS meets their needs? Have you heard stories about the experiences of patients who have undergone RAS? (from own hospital or other). Can you describe a specific story? Has this influenced your opinion of RAS?</p>
<p>CFIR Cost</p>	<p>20. How do you think the cost associated with RAS systems affects the use/uptake of it?</p>	
<p>TDF Social Professional Role &amp; Identity</p>	<p>21. Do you think the delivery of RAS should be a standard part of your professional role?</p> <p>22. Do you think the wider uptake of RAS would change the nature of your role?</p>	<p>If yes, in what way? How do you feel about this?</p>
<p>TDF Memory, Attention and Decision Making</p> <p>TDF Environmental Context and Resources</p>	<p>23. Do you think RAS will change how you work? What about for the rest of the surgical team?</p> <p>24. [theatre staff] Do you think RAS changes your situation awareness in the operating room? How does this impact on decision making?</p>	<p>Changes in physical demands of surgery or mental demands (task complexity – link to question about communication requirements).</p> <p>Physical layout changes in the operating room, how do you think this would influence communication? How do you think RAS might change/does change the workflow within the operating theatre?</p>



## Interview topic guide

		Do you think these changes, in workload, (potentially) brought about by RAS would be/are applicable across specialities?
		Situation awareness – probe: Changes in visual and tactile feedback available to you – what impact does RAS have on this? How do you think this might affect patient outcomes?
TDF Emotions	25. How do you feel about having RAS in your centre? Do you think it affects your credibility? Does it make you feel good? Does it provoke fear? Does it give you concerns?	Are you apprehensive, confident, excited? Why do you feel that way?
<b>Target framework domain/construct</b>	<b>Question (perceptions on the future direction of RAS)</b>	<b>Probe(s)</b>
TDF Optimism	26. What do you think the future of RAS will look like?	Overall, do you expect RAS to be used (more frequently) in the future? Why?
CFIR Tension for change	27. Do you see a need for implementing RAS more widely, outside of your organisation? E.g. should there be a robot in every hospital?	
TDF Beliefs about Consequences	28. What potential concerns, if any, does the future of RAS raise for you? [that we haven't covered already]	
TDF Environmental Context and Resources	29. How do you think NHS circumstances, e.g. in terms of set up and response to COVID, might influence the provision of RAS in the future?	



## Interview topic guide

TDF Goals, CFIR Relative Advantage	30. In your view, where does investing in RAS sit in the hierarchy of developments that you think are required to improve surgery for the next decade?	
CFIR Complexity	31. Last question! What in your view would be required to move RAS from being in the nice-to-have bracket to the must-have? Is this level of change achievable? Is the effort worth it in your view?	

**Any other issue you would like to raise?**

**Thank you for your time [reassure about confidentiality and contact information if any questions].**

## COREQ (CONsolidated criteria for REporting Qualitative research) Checklist

A checklist of items that should be included in reports of qualitative research. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Topic	Item No.	Guide Questions/Description	Reported on Page No.
<b>Domain 1: Research team and reflexivity</b>			
<i>Personal characteristics</i>			
Interviewer/facilitator	1	Which author/s conducted the interview or focus group?	
Credentials	2	What were the researcher's credentials? E.g. PhD, MD	
Occupation	3	What was their occupation at the time of the study?	
Gender	4	Was the researcher male or female?	
Experience and training	5	What experience or training did the researcher have?	
<i>Relationship with participants</i>			
Relationship established	6	Was a relationship established prior to study commencement?	
Participant knowledge of the interviewer	7	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	
Interviewer characteristics	8	What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topic	
<b>Domain 2: Study design</b>			
<i>Theoretical framework</i>			
Methodological orientation and Theory	9	What methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis	
<i>Participant selection</i>			
Sampling	10	How were participants selected? e.g. purposive, convenience, consecutive, snowball	
Method of approach	11	How were participants approached? e.g. face-to-face, telephone, mail, email	
Sample size	12	How many participants were in the study?	
Non-participation	13	How many people refused to participate or dropped out? Reasons?	
<i>Setting</i>			
Setting of data collection	14	Where was the data collected? e.g. home, clinic, workplace	
Presence of non-participants	15	Was anyone else present besides the participants and researchers?	
Description of sample	16	What are the important characteristics of the sample? e.g. demographic data, date	
<i>Data collection</i>			
Interview guide	17	Were questions, prompts, guides provided by the authors? Was it pilot tested?	
Repeat interviews	18	Were repeat interviews carried out? If yes, how many?	
Audio/visual recording	19	Did the research use audio or visual recording to collect the data?	
Field notes	20	Were field notes made during and/or after the interview or focus group?	
Duration	21	What was the duration of the interviews or focus group?	
Data saturation	22	Was data saturation discussed?	
Transcripts returned	23	Were transcripts returned to participants for comment and/or	

Topic	Item No.	Guide Questions/Description	Reported on Page No.
		correction?	
<b>Domain 3: analysis and findings</b>			
<i>Data analysis</i>			
Number of data coders	24	How many data coders coded the data?	
Description of the coding tree	25	Did authors provide a description of the coding tree?	
Derivation of themes	26	Were themes identified in advance or derived from the data?	
Software	27	What software, if applicable, was used to manage the data?	
Participant checking	28	Did participants provide feedback on the findings?	
<i>Reporting</i>			
Quotations presented	29	Were participant quotations presented to illustrate the themes/findings? Was each quotation identified? e.g. participant number	
Data and findings consistent	30	Was there consistency between the data presented and the findings?	
Clarity of major themes	31	Were major themes clearly presented in the findings?	
Clarity of minor themes	32	Is there a description of diverse cases or discussion of minor themes?	

Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*. 2007. Volume 19, Number 6: pp. 349 – 357

**Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.**

# BMJ Open

## Current issues and future considerations for the wider implementation of robotic-assisted surgery: a qualitative study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-067427.R1
Article Type:	Original research
Date Submitted by the Author:	13-Oct-2022
Complete List of Authors:	<p>Lawrie, Louisa; University of Aberdeen, Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition</p> <p>Gillies, Katie; University of Aberdeen, Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition</p> <p>Davies, Loretta ; University of Oxford, RCS Surgical Interventional Trials Unit (SITU), Nuffield Dept Orthopaedics, Rheumatology and Musculoskeletal Sciences</p> <p>Torkington, Jared; University Hospital of Wales Healthcare NHS Trust, Department of Colorectal Surgery</p> <p>McGrath, John; Royal Devon and Exeter NHS Foundation Trust, Department of Urology</p> <p>Kerr, Richard; Royal Devon and Exeter Hospital, Department of Neurosurgery</p> <p>Immanuel, Arul; Newcastle Upon Tyne Hospitals NHS Trust, Northern Oesophago-Gastric Unit</p> <p>Campbell, Marion; University of Aberdeen, Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition</p> <p>Beard, David; University of Oxford, RCS Surgical Interventional Trials Unit (SITU), Nuffield Dept of Orthopaedics, Rheumatology and Musculoskeletal Sciences</p>
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Surgery
Keywords:	QUALITATIVE RESEARCH, SURGERY, HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Current issues and future considerations for the wider implementation of**  
4 **robotic-assisted surgery: a qualitative study**  
5  
6  
7

8  
9 Louisa Lawrie<sup>1\*</sup>, Katie Gillies<sup>1</sup>, Loretta Davies<sup>2</sup>, Jared Torkington<sup>3</sup>, John McGrath<sup>4</sup> Richard  
10  
11 Kerr<sup>5</sup>, Arul Immanuel<sup>6</sup>, Marion K Campbell<sup>1+</sup>, David J Beard<sup>2+</sup>  
12  
13

14  
15 <sup>1</sup> Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical  
16 Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, UK.  
17

18  
19 <sup>2</sup> RCS Surgical Interventional Trials Unit (SITU), Nuffield Dept Orthopaedics, Rheumatology and  
20 Musculo-skeletal Sciences, University of Oxford, UK.  
21

22  
23  
24 <sup>3</sup> Department of Colorectal Surgery, University Hospital of Wales Healthcare NHS Trust, Heath Park,  
25 Cardiff, UK.  
26

27  
28  
29 <sup>4</sup> Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.  
30

31  
32 <sup>5</sup> Department of Neurosurgery at Oxford Radcliffe Hospitals NHS Trust, UK.  
33

34  
35 <sup>6</sup> Northern Oesophago-Gastric Unit, Newcastle Upon Tyne Hospitals NHS Trust, UK.  
36  
37  
38  
39  
40

41 \*Correspondence to:

42  
43 Louisa Lawrie

44  
45 Health Services Research Unit, Institute of Applied Health Sciences, School of Medicine, Medical  
46 Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, UK  
47

48  
49 E-mail: [louisa.lawrie1@abdn.ac.uk](mailto:louisa.lawrie1@abdn.ac.uk)  
50  
51

52  
53  
54  
55 + Joint senior authors  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** The effective implementation of a fast-changing healthcare delivery innovation, such as robotic-assisted surgery (RAS), into a healthcare system, can be affected (both positively and negatively) by external contextual factors. As part of a wider project investigating ways to optimise the implementation of RAS, this qualitative study aimed to uncover current issues of RAS and predictions about the future of robotic surgery. We refer to 'current issues' as the topical and salient challenges and opportunities related to the introduction of RAS in the UK healthcare system, from the perspectives of key stakeholders involved in the delivery and implementation of RAS.

**Design:** Semi-structured interviews and focus groups were conducted. A thematic analysis was conducted to summarise salient issues that were articulated by participants.

**Setting and participants:** The interview sample (n = 35) comprised surgeons, wider theatre staff and other relevant personnel involved in the introduction and delivery of RAS services across the UK, including service managers and policy-makers/commissioners. Two focus groups were also conducted with surgical trainees (n = 7) and members of the public (n = 8), respectively.

**Results:** The results revealed a largely positive attitude towards the introduction of RAS technology and an expectation of continued rapid expansion. Areas perceived to be particularly pertinent and requiring ongoing attention were also highlighted, including the need to achieve improved quality control, expertise quantification and training issues, and the need to educate the public. Issues of centralisation, service organisation and equity of access were also emphasised.

**Conclusions:** Our study has highlighted a range of issues perceived to be particularly pertinent to the current and future provision of RAS which should be addressed. The areas outlined can



1  
2  
3 enable healthcare managers and surgeons to plan for the adoption and/or expansion of RAS  
4  
5 services.  
6  
7  
8  
9

10  
11 **Keywords:** Robotic Assisted Surgery; Implementation of RAS; Qualitative Research; Health  
12  
13 Services.  
14  
15

16  
17  
18  
19 Word count: 6112  
20  
21  
22

### 23 **Strengths and limitations of this study**

- 24 • This qualitative research provides insights into specific areas of focus for surgeons and  
25 managers currently planning adoption or expansion of robotic-assisted surgery.
- 26 • Stakeholders from several specialties were sampled, as well as surgical trainees, members  
27 of the public and health service managers.
- 28 • The sample for interview comprised mostly of surgeons; the lack of variation in roles  
29 within our interview sample could be regarded as a limitation.
- 30  
31  
32

## 33 34 35 36 **INTRODUCTION**

37  
38  
39  
40 There is increasing global adoption of robotic-assisted surgery (RAS) as a result of the  
41 suggested benefits for ergonomics, surgical precision, enhanced tissue visibility, reduced  
42 requirement for surgical assistance, improved training and workflow practices(1–5). Further  
43 expansion of robotic surgical systems is also forecast(4,6,7). The implementation of RAS, as a  
44 relatively new technology and having substantial differences to existing surgical healthcare  
45 delivery, can be considered “disruptive” (it requires system change), and several areas of new  
46 knowledge may be required to facilitate widespread implementation(8,9). Furthermore, the  
47 introduction of fast changing technology can be susceptible to misinformation, sensationalism,  
48 and early adoption bias(10,11). It is therefore critical to obtain a balanced and representative  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 picture of current issues that could potentially affect wider implementation or roll out. This  
4  
5 information can help with decision making, inform evolving implementation plans and ongoing  
6  
7 clinical pathway development, ultimately leading to better patient care.  
8  
9

10  
11 This study was part of a wider project set up to formally explore the barriers and facilitators  
12  
13 to the implementation/scale up of RAS services at different stages of the implementation  
14  
15 process, focusing on both technology-specific and behavioural influences. The broad aim of  
16  
17 this element was to uncover and report current issues of RAS and predictions about the future  
18  
19 of robotic surgery. We refer to current issues as the topical and salient challenges and  
20  
21 opportunities related to the introduction of RAS in the UK healthcare system, from the  
22  
23 perspectives of key stakeholders involved in the delivery and implementation of RAS.  
24  
25  
26  
27  
28  
29

## 30 **METHODS**

### 31 **Study design**

32  
33  
34 This was a qualitative study using semi-structured interviews and focus groups. The  
35  
36 Consolidated Criteria for Reporting Qualitative Research was employed for the study  
37  
38 report(12). This study was part of a wider project (13) examining the barriers and enablers to  
39  
40 the implementation of RAS using approaches from behavioural and implementation science.  
41  
42 The questions within the interview topic-guide (see online supplementary file 1) were primarily  
43  
44 developed to examine the factors that affect the implementation of RAS from a behavioural  
45  
46 and technology-specific perspective, but also included broader questions about general  
47  
48 perceptions of RAS. The present study reports findings from the concurrent inductive analysis  
49  
50 of the data regarding current contextual issues surrounding RAS.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The present study also involved two focus groups with surgical trainees and the public,  
4 respectively. Focus group questions were designed to gauge general perspectives in terms of  
5 participants' understanding of RAS (most notably for the public focus group), the advantages  
6 and disadvantages of RAS (relevant to both focus groups), the future of RAS and the  
7 consequences of RAS adoption on skills development (Surgical Trainees focus group).  
8  
9  
10  
11  
12  
13  
14

15 Initial key informant/pilot interviews were conducted with individuals who had significant  
16 experience of RAS to test the suitability of our interview topic guide (in terms of  
17 comprehensibility, acceptability, and relevance). The key informant interviews included a  
18 highly experienced RAS Surgeon, an industry representative and a Scrub Nurse. Interview  
19 guides were adapted as a result of these interviews to ensure that the questions were relevant  
20 to each participant role (e.g. surgeons, nurses, and industry partners). The topic-guide was  
21 iteratively updated as the interviews progressed.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## 32 **Participants**

### 33 **Semi-structured interviews**

34  
35  
36  
37  
38 The sample was purposively selected to contain surgeons, wider theatre staff and other relevant  
39 personnel involved in the introduction and delivery of RAS services across the UK, including  
40 service managers and policy-makers/commissioners. We aimed to interview stakeholders from  
41 a range of hospital sites across the UK and include a range of views (e.g. proponents and  
42 opponents) and experiences of RAS (i.e. variations in specialty and duration of RAS  
43 experience). A pre-specified sample of 35 was included to ensure full representation of  
44 stakeholders and saturation of themes. We also judged the sufficiency of our sample size based  
45 on the principles outlined by Francis and colleagues(14). Participants were identified through  
46 clinical and research networks, such as the Royal College of Surgeons of England Robotic &  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Digital Research (RADAR) group, surgical research networks, industry connections and local  
4  
5 hospital knowledge. A broad range of disciplines and representation was sought.  
6  
7  
8  
9

#### 10 11 Focus group: surgical trainees 12

13  
14 Early career surgical trainees from various specialties were purposefully selected to  
15  
16 complement the interview data - which mostly represented clinical viewpoints from established  
17  
18 surgeons at later stages of their careers or other non-surgical staff. The trainee group were  
19  
20 accessed and invited through National Surgical Trainee Collaboratives.  
21  
22

#### 23 24 Public focus group 25

26  
27 A further focus group was held with members of the public (linked to the Health Services  
28  
29 Research Unit) to establish their perspectives about robotic assisted surgery, including the  
30  
31 outcomes they thought were important to them when evaluating RAS.  
32  
33

### 34 35 **Data collection** 36

37  
38 Following piloting, the interviews were led by LL, accompanied by MC or DB to ensure that  
39  
40 all technical aspects of issues related to RAS were covered. This was also conducted to allow  
41  
42 clarification of issues for both interviewer and interviewee, utilising the expertise of the  
43  
44 authors. All interviews were conducted via Microsoft Teams(15) and audio-recorded. Data  
45  
46 collection took place between October 2020 and March 2021. The interviews were transcribed  
47  
48 verbatim by an external transcription company, anonymised, and reviewed for accuracy (LL)  
49  
50 by (re)checking against the audio recordings where necessary (e.g. where extracts of the  
51  
52 transcripts were highlighted as 'inaudible'). Transcripts were subjected to the analysis process  
53  
54 outlined below.  
55  
56  
57

### 58 59 **Data analysis** 60

1  
2  
3 A thematic data-driven inductive approach to analysis(16) was adopted to explore wider  
4 contextual perspectives on current and potential future issues of RAS. Following  
5 review/refinement of themes, a thematic framework was developed (LL, reviewed by KG, MC,  
6 DB) which described the content of all themes with illustrative quotes to facilitate data analysis.  
7  
8 A double coder (LD) checked the themes accurately described the content of participants'  
9 responses in five diverse transcripts. Any coding discrepancies identified during this process  
10 were discussed (between LL and LD) to reach consensus. Data analysis was supported through  
11 using NVivo(17) and Microsoft Excel(18).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 **Patient and public involvement**

23  
24  
25 None.  
26  
27

## 28 **RESULTS**

### 29 **Demographics**

30  
31  
32  
33  
34 Sample demographics are provided in Table 1. In total, 35 stakeholders were interviewed.  
35  
36  
37 Twenty-two clinical stakeholders (including surgeons, wider theatre staff and service  
38 managers) across a range of clinical specialties were sampled from a total of 16 National Health  
39 Service (NHS) hospital sites located across England, Scotland, and Wales. The robotic  
40 operations conducted (or assisted) by clinical stakeholders varied and included body cavity-  
41 based work (most often cancer) in colorectal, upper gastrointestinal, thoracic, head and neck,  
42 urology, gynaecology, and orthopaedics. Orthopaedics is slightly different (knee, hip, and  
43 spine), as it is mainly related to accuracy of cutting bone rather than the manipulation of  
44 instruments inside a body cavity.  
45  
46  
47  
48  
49  
50  
51  
52  
53

54  
55  
56 Seven surgical trainees participated in the trainee focus group. Five trainees were sampled  
57 from five different UK hospital sites, two were from international institutions at the time of  
58  
59  
60

interview (but acquired previous clinical practice in the UK). Trainee specialties are summarised in Table 1. All trainees had experience of assisting in at least one robotic case, and two were undertaking robotic surgical fellowships.

Eight individuals participated in the public focus group. Prior to the public focus group, participants attended an information session led by a surgeon. This session was designed to introduce RAS, provide information regarding the conduct of RAS and acted as an opportunity for the public to ask questions. None of the participants reported having had a robotic assisted procedure, although some indicated their patient experience of other types of keyhole surgery.

<b>Characteristic</b>	<b>Interviews</b>	<b>Trainee focus group</b>
	<i>N</i> = 35	<i>N</i> = 7
<b>Age</b>		
Median	50	35.5
Range	30-70	31-37
<b>Gender</b>		
Female	7	4
Male	27	2
<b>Ethnicity (self-identified)</b>		
Asian British	3	-
Caucasian	29	5
Indian	1	-
Other white background	1	-
Chinese Asian	-	1
<b>Role</b>		
National Surgical Specialty Leader	5	-
Surgeon (RAS user)	11	-
Surgeon (Non-RAS user)	2	-
Scrub Nurse	2	-
Industry representative	5	-
Policy Commissioner	5	-
Surgical Trainee	2*	7
Anaesthetist	1	-
Service Manager	2	-
<b>Specialty (Leaders, Surgeons, Trainees)</b>	<i>N</i> = 20	
Urology	5	-
Colorectal	8	1
General	2	1
Orthopaedics	3	2
Gynaecology	1	1
Thoracic	1	2

## Table 1. Demographic data for the interviewees and focus group (trainee) participants

*Note:* Age, gender, and ethnicity was not recorded for 1 interview participant and 1 focus group (trainee) participant. \* Trainees in the interview sample were not in the trainee focus group.

### Findings

Participants raised several key issues influencing the current provision and implementation of RAS in the NHS. The issues identified related to the evolution and future direction of RAS services, as well as issues that affect service implementation including workforce training, governance, and the potential for de-skilling. The impact of external influences, particularly public perceptions, was also highlighted. These are discussed in more detail below and summarised in Figure 1.

### Evolution and future direction of RAS

#### Rapid evolution of RAS

RAS was perceived to be evolving at a rapid pace in terms of both widespread adoption and robotic technological advancements. Some participants positively highlighted the need for healthcare systems to embrace this evolutionary process:

“...As robotics are evolving, the NHS needs to be involved because the surgeons and clinicians and all NHS staff would be left behind if they weren’t involved now.” Industry stakeholder, P2I26.

However, others emphasised the need for the wider system and evaluation (evidence) to catch up to allow a more joined-up roll-out going forward. Some noted that the rapid uptake of RAS meant that evaluative studies investigating the technology often lagged behind the adoption:

1  
2  
3 “... so I think that’s where the big data, where the registries and where the collaborative multi-centre  
4 cohort studies data will be very useful....by the time you get level one data it will have moved on...,  
5  
6 people would have learned the technology, they would have believed in it and they would have  
7  
8 [already] moved on to the next thing.” RAS Surgeon, P11S.  
9

10  
11  
12 However, participants also acknowledged the challenges associated with conducting  
13 meaningful evaluation alongside rapid roll-out, particularly in learning curve phases but also  
14 when clinician equipoise might be evolving or where patient preference is strong:  
15  
16

17  
18  
19 “...you will have more robotic surgeons who are experienced, trained and on the learning curve...  
20 over the learning curve they’ll find it difficult to recruit patients into the laparoscopic arm of the  
21 study.” RAS Surgeon, P12S.  
22  
23  
24  
25

26  
27 The need to demonstrate the benefits of RAS, particularly longitudinally and those that are  
28 not immediately visible was stressed. Whilst this is not unique to RAS, it was acknowledged  
29 that good cost-effectiveness data would aid the greater implementation of RAS:  
30  
31  
32

33  
34 “It’s quite important I think to actually quantify this benefit economically.... So it’s not just the  
35 length of stay in hospital, it’s also their return of function in the community and it’s the lesser  
36 or the sparing of community resources.” RAS Surgeon, P11S.  
37  
38  
39  
40  
41  
42  
43

#### 44 Future direction of RAS

45  
46  
47 There was widespread perception that RAS is “here to stay” and will be more commonplace in  
48 the future. A minority of interviewees felt RAS might be something of a fad that may go out  
49 of fashion. Overall, there was a perception that progress was strongly linked to the ongoing  
50 routine digitisation and technological advance in healthcare:  
51  
52  
53  
54

55  
56  
57 “Everything has a screen on it now. Everything is digitised. We’re going down that path.” Scrub  
58 Nurse, P12N  
59  
60



1  
2  
3 “So yes, definitely evidence is a big part of that, but we all know we also need to see advances in  
4 the technology. But the advances in the technology will come as the robots become used more.”

5  
6  
7 Specialty Leader, P2S21  
8  
9

10 However, there were some concerns that COVID-19 might negatively influence the provision  
11 of RAS in the future, due to the financial constraints within the NHS exacerbated by the  
12 pandemic:  
13  
14

15  
16  
17 “I do worry a little bit that constraints over the next two or three years are going to be quite daunting  
18 in terms of I think money [for RAS] is going to be tight and it is tight within the NHS... whether  
19 that’s with COVID or I don’t know.” Scrub Nurse, P12N.  
20  
21  
22  
23

24  
25 Clinical participants provided insights on the dynamic nature of the RAS market, including  
26 perceptions on how RAS might evolve. Some participants indicated that surgical robots would  
27 likely become more autonomous in the future. There were also comments related to the  
28 potential of RAS to be conducted by surgeons who are located overseas/physically distant from  
29 the theatre:  
30  
31  
32  
33  
34

35  
36  
37 “So I could be in my office now doing work but one of my team could be in trouble in the  
38 operation and they could literally just log on to the computer and show me what they’re doing and  
39 I could say, “Okay, I’ll take over the controls and I’ll just fix that”.” Specialty Leader, P2S21.  
40  
41  
42  
43

44 One industry stakeholder indicated that surgeons may become more comfortable with the  
45 prospect of receiving virtual expert RAS guidance/assistance due to remote care becoming  
46 more commonplace during the COVID-19 pandemic:  
47  
48  
49

50  
51 “...we’ve learnt a lot about how you can be more in places at once ...so I think Covid is helping us  
52 through that. I think a surgeon is going to be much more comfortable getting expert advice from  
53 somebody that’s nowhere even near them..” Industry representative, P2I24.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 However, some participants from the public focus group expressed concerns about the  
4 possibility of a more remote model of care, indicating that they would feel more comfortable  
5 in the presence of a surgeon during the entirety of a RAS procedure:  
6  
7  
8  
9

10  
11 “I think I’d want to be reassured that there was going to be a surgeon or any other kind of doctor  
12 there permanently throughout the entire operation in case something went south.” Participant 5,  
13 public focus group.  
14  
15

16  
17  
18 “So I’d probably what to ask what’s the plan B when things suddenly go pear shaped, I don’t want  
19 to end up in an operation theatre with all the robotic hands sticking in me and then no-one knows  
20 what to do...”. Participant 6, public focus group.  
21  
22  
23

24  
25 Many clinical participants indicated that the capital cost of RAS is expected to decrease, and  
26 some linked this to the potential introduction of new companies to the market:  
27  
28

29  
30 “I think the instruments, the prototypes, the equipment is going to evolve, it’s going to continue to  
31 change, it’s going to be more powerful, it’s going to be more intelligent, it’s going to be less  
32 expensive.” Specialty Leader, P01S.  
33  
34

35  
36  
37 “I can only see at some stage ... the cost will come down further and is coming down because there’s  
38 more competition in the market.” Scrub Nurse, P12N.  
39  
40  
41  
42  
43  
44

## 45 Role of industry

46  
47  
48 There were mixed views on the role and involvement of industry within current and future RAS  
49 service provision. Many participants indicated the positive opportunities that could arise from  
50 a collaborative relationship with industry, citing that the UK does not often embrace industry-  
51 led partnerships and perhaps should. The capability of industry to facilitate training, utilise  
52 better resources and form more of a collaborative approach to development was expressed by  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 “Industry is traditionally almost a dirty word in surgery and even more with surgical academics.  
4  
5 However, like many things I believe we are historically behind our European and US colleagues in  
6  
7 our involvement with industry.” Participant 7 Focus group Surgical Trainee.  
8  
9

10 Some participants, however, voiced a wish for greater independence in regard to issues such  
11  
12 as RAS training in the future and wished to have more control of the strategy:  
13  
14

15 “...I think we need to...seriously think about taking control of our own training in robotics or at  
16  
17 least having more of a role in collaborating with industry.” Participant 6 Focus group Surgical  
18  
19 Trainee.  
20  
21

22 Particular concerns regarding market dominance were also expressed:  
23  
24

25 “....The problem is a lot of robotic proponents are now employed by industry to become their  
26  
27 proctors or key opinion leaders and that then becomes very awkward... I think right now, robotic  
28  
29 surgery is industry driven, but I think we need to change that. And I think once we change that,  
30  
31 you’ll see a huge upscaling.” Surgical Trainee (Interviewee), P2S17.  
32  
33

34  
35  
36  
37 Acknowledging that RAS was likely to be part of the NHS for some time to come,  
38  
39 stakeholders raised a number of further points for discussion – as discussed below.  
40  
41

### 42 **The need for guidance, governance, regulation, and quality control**

43  
44

45 While RAS was acknowledged to be evolving at a rapid pace, clinical participants expressed  
46  
47 the need for national guidance to support adoption and future expansion. Many suggested a  
48  
49 national framework to support implementation, including training standards would be  
50  
51 beneficial. Relatedly, many participants verbalised support for national regulatory mechanisms  
52  
53 in place to ensure appropriate delineation of surgical responsibilities to avoid potentially  
54  
55 problematic situations arising:  
56  
57  
58  
59  
60

1  
2  
3 “So my concern.... is the worry that if things do not go according to the plan it’s very easy to blame  
4 the technology.... We have seen that with certain technologies ... and surgeons start to blame the  
5 equipment and the technique. So just there has to be some governance around the introduction and  
6 sudden...explosive expansion of that technology.” RAS Surgeon, P12S.  
7  
8  
9

10  
11  
12 “You could imagine .....if something were to go wrong in that [RAS] situation then that would cause  
13 a huge stir and would have a negative effect on ....trainees, certainly surgeons, and the public’s  
14 perception of robotic surgery”. Surgical Trainee (Interviewee) P2S12.  
15  
16  
17

18  
19 The capability of RAS to automatically generate accurate and substantial mechanical and  
20 outcome data was seen as a strong positive and of significant benefit for training, quality  
21 assurance and accreditation purposes. The versatility of RAS and its incorporation with other  
22 technological advances (Artificial Intelligence (AI), machine learning, big data) further  
23 strengthened this position:  
24  
25  
26  
27  
28  
29

30  
31 “I think first of all you can train your surgical workforce better...It allows you to use new tools i.e.  
32 augmented reality, mixed reality, simulation and robotics and use data for transition from one state  
33 to another and currently we don’t have. So data will also help us train our workforce differently and  
34 more effectively, that’s number one...” RAS Surgeon, P15S.  
35  
36  
37  
38  
39

40 However, the acceptability of standard data collection/monitoring facilitated by RAS within  
41 theatre practices still needs debate such that it would not be seen as a somewhat a “Big Brother”  
42 development which could be misused:  
43  
44  
45  
46  
47

48 “...[some] people .. wouldn’t necessarily want that...level of monitoring like you have in the black  
49 box in an aircraft is not appropriate for surgery. I think that’s an ongoing debate that needs to be  
50 addressed... it kind of introduces a Big Brother culture of what goes on in an operating theatre, a  
51 previously sacred environment, and essentially it’s eavesdropping on that.” Industry representative,  
52  
53  
54  
55  
56 P03I.  
57  
58  
59  
60

## Workforce issues: training to support RAS and future potential for deskilling

### Workforce training needs

In addition to the need for increased governance, there was also a perceived ongoing need to adapt the capacity and structure of NHS training for RAS to optimise readiness for further RAS expansion among the workforce. Both surgeons and trainees mentioned the imperative to be able to achieve minimal competence and overcoming the learning curve, especially whilst RAS surgery is not the norm within the NHS for most surgical specialties. Whilst outside specialist training centres provide support, there was a suggestion that RAS surgery training may be in its infancy and required expansion. There was the perception that experienced surgeons are more easily accommodated in the RAS training setting currently, but that trainees should also be catered for.

“But also outside of the theatre with the training modules and things you’d hope that there’s this opportunity to practice 100 times before you go near a patient. I do see this dichotomy between that promise, which has been around for a while now and what is actually available to trainees, and I think at the moment at least it’s seen as something which is for advance laparoscopic consultants.”

Focus Group Surgical Trainee, Participant 1.

### Potential for workforce deskilling

Participants also highlighted the potential that the expansion of RAS may result in deskilling the workforce in other surgical approaches (especially open surgery) in the future – as was seen with the roll out of other minimally invasive surgery. Widespread adoption of RAS may limit exposure to, and create diminished skills of, open surgery or non-RAS endoscopic surgery amongst the surgical community:

1  
2  
3 “There may be a loss of an open skill set and obviously trainees aren’t getting as much hands on  
4 during cases if they don’t have the basic robotic training done.” Focus group Surgical Trainee,  
5 Participant 6.  
6  
7  
8  
9

10 However, this was countered by others who reported that performing minimally invasive  
11 procedures, in which RAS is embedded, enhanced overall surgical capability and proficiency.  
12  
13

14 In such a case the emphasis is on upskilling, rather than deskilling:  
15  
16

17  
18 “...the reality is laparoscopic surgery is actually technically more challenging than open surgery.  
19 You have to have, in a way, a better understanding, or at least the same understanding, of the  
20 anatomy, and I don’t know any good laparoscopic surgeons who aren’t good open surgeons as well.”  
21  
22  
23  
24 RAS Surgeon, P2S11.  
25  
26  
27  
28  
29

### 30 **Service design issues: centralisation, and equity of access**

31

#### 32 Centralisation or distributed services

33

34  
35 Some participants held strong views about the concept of centralisation: the idea that RAS  
36 should be delivered by specialist centres in specific regions of the UK. Proponents of  
37 centralisation cited that any fragmentation of RAS services could be detrimental because of the  
38 low case volumes of individual surgeons and a subsequent lack of quality control. They also  
39 argued that centralisation is a preferred model because of the team approach requirement:  
40  
41  
42  
43  
44  
45  
46

47  
48 “...I think you need to centralise this practice [RAS], you need to invest more robotic platforms in  
49 selected hospitals.” RAS Surgeon, P12S.  
50  
51

52  
53 There was variability in the perception of suitability for centralisation for different specialties.  
54  
55 One participant highlighted the value of centralisation in relation to RAS Urology services in  
56 the UK specifically, but expressed concerns regarding the practicalities of centralising practices  
57  
58  
59  
60

1  
2  
3 for other specialties. They also highlighted the complexities associated with the fragmented  
4 development of multi-specialty RAS services across the UK.  
5  
6  
7

8 In line with the arguments for centralisation, some participants compared the organisation of  
9 services in the UK and US, suggesting that centralisation of RAS practices can be an ideal  
10 method of maximising surgical volume with resultant positive clinical outcomes:  
11  
12  
13

14  
15  
16 “I would like to see the complex surgeries done in centres of excellence by teams, not by individuals,  
17 and moving through high volumes...” Industry stakeholder, P2I13.  
18  
19

20  
21 Relatedly, participants verbalised their views around the likely or ideal configuration of RAS  
22 service provision in the future. Some participants drew upon their observations of surgical care  
23 during COVID-19, indicating that the lessons garnered from using mixed models of service  
24 delivery in the UK could be applied to RAS:  
25  
26  
27

28  
29  
30  
31 “I think one of the things COVID has shown us that the way our model of mixing up emergency  
32 care and elective care has caused significant harm to people who didn’t have COVID sadly and that  
33 will die of other reasons i.e. cancer not being treated and other things. I’d even look at models [of  
34 RAS] with elective care is separate from emergency care.” Specialty Leader, P15S.  
35  
36  
37  
38  
39  
40  
41  
42

### 43 Equity of access

44  
45 There were also concerns about the current set up of RAS and the need for equity of access for  
46 the population to the best interventions:  
47  
48  
49

50  
51 “... there is a strong correlation between the poorer parts of the UK and the lack of access to any  
52 minimally invasive surgery, and then following on from that, robotic surgery...” Industry  
53 representative, P03I.  
54  
55  
56  
57

58 This theme was also highlighted by commissioners who stressed the need to make the strategy  
59 for expanding RAS services across certain areas of the UK, equitable:  
60

1  
2  
3 “... a big problem in [one region of the UK], we have huge inequalities, and if it ends up that the  
4 middle-class get the robot and the rest get the other... down the road, well that’s not so good, is it?  
5  
6 ... Again, we don’t want to create more inequalities.” Policy-maker/commissioner, P2SM20.  
7  
8  
9

10 In contrast, some also suggested that RAS can provide equitable surgery and improve patient  
11 access to minimally invasive surgery:  
12  
13

14  
15 “You could argue that if it [RAS] increases access to minimally invasive surgery, then that could fit  
16 in with that ethos of levelling things up, of providing equitable surgery that the best surgery to  
17 everyone. I think the difficulty is always going to be around the initial cost” Specialty Leader, P01S.  
18  
19  
20  
21  
22  
23  
24

### 25 **Need for improved public understanding**

26  
27  
28 As well as perceived challenges associated with the NHS accommodating service and training  
29 issues, the interviews and focus groups highlighted the lack of public understanding of RAS  
30 and the importance of educating the public about what to expect from RAS:  
31  
32  
33

34  
35  
36 “...there’s a real patient expectation problem sometimes, where people felt it was going to be  
37 magical... it’s a common one... the ‘sparkle dust’ problem. People think it’s new and it’s going to  
38 have no problems.” Surgeon (non-RAS user), P2S6.  
39  
40  
41

42  
43 “So at the moment there’s a complete misunderstanding around robotics, and what it is. If you say  
44 to a patient, what’s their perception of it...not in a medical context, they think about big machines  
45 putting cars together in factories and Amazon packaging up parcels. As a result, artificial intelligence  
46 and robotics terminology has become mixed, and the perception of a robot is for surgery is actually  
47 largely around artificial intelligence. When you then talk through the fact that there’s a surgeon  
48 involved all the time, they’re connected, they’re in the operating theatre, a lot of the fears and things  
49 start to disappear. But the problem is, you have to have that conversation at an individual level at  
50 the moment. There’s not that common awareness that a robot that’s used for surgery is very different  
51 to a robot that, for instance, is used to assemble a car.” Industry representative, P03I.  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Participants in the public focus group indicated a need for greater information and  
4 understanding around RAS terminology, to avoid further misconceptions about what robotic  
5 (assisted) surgery actually entails, particularly to address misconceptions about issues such as  
6 the level of autonomy afforded to the surgeon and how dominated it is by independent AI  
7 technology. There was little true understanding of the “tool” aspect of RAS and the primary  
8 control/replication model:  
9  
10  
11  
12  
13  
14  
15

16  
17  
18 “...I would be very keen to know what degree of control the doctor has, because whether you call it  
19 robotic assisted or robotic, the term “robot” is there, and if there’s a bit at the end saying “assisted”  
20 it’s not hugely relevant I think if you were quite fearful about going into surgery. So for me I would  
21 really want to know that there was (a) going to be a doctor present, ...there’s no indication that if  
22 it’s robotic surgery that there will be, and also to know that it is still the doctor who’s in charge. So  
23 I think, I mean I think that point about language is a really significant one.” Public focus group  
24 participant 7.  
25  
26  
27  
28  
29  
30  
31  
32

33 However, public focus group participants also highlighted the importance of continuing to  
34 place trust in the Surgeon, regardless of the surgical method deployed. In terms of benefit, one  
35 participant perceived RAS to be more beneficial than other types of keyhole surgery.  
36  
37  
38  
39

40  
41 “It seems to be more or less the same thing inside the body, a tube with a tool at the end of it and I’d  
42 rely on the surgeon, I trust the surgeon and I’m sure they’re equally skilled in either manoeuvre. So  
43 I know that robotics could do more for me than keyhole, but I would be happy to leave the best  
44 choice to the surgeon”. Public focus group participant 2.  
45  
46  
47  
48  
49

50 Many clinical and industry stakeholders highlighted the notion that the public often perceive  
51 RAS in a disproportionately positive manner, often equating advanced technology with  
52 superior care. There were suggestions that there may be some value in educating the public to  
53 ensure appropriate expectations of RAS, especially in any roll out period. The undue influence  
54 of media was also highlighted, reinforcing the need for accurate public information to be  
55  
56  
57  
58  
59  
60

1  
2  
3 developed and disseminated:  
4  
5

6 “there was a huge media thing around it [a famous person getting robotic surgery]. Because they  
7  
8 were treated robotically, there was a very large uptake in patients going to hospitals or going through  
9  
10 screening, and so suddenly it went up.” Industry representative, P03I.  
11  
12

## 13 **DISCUSSION**

14  
15

16 This study derived from a broad sample of high engagement RAS personnel, highlighted a  
17  
18 range of issues particularly pertinent to the current provision of RAS and to future service needs  
19  
20 which require more urgent consideration.  
21  
22

23  
24 The rapid evolution of RAS for an institution such as the NHS was largely welcomed but  
25  
26 offset with the need to ensure that training capacity and patient education kept up in parallel.  
27  
28 Such reservation was highlighted further by an expressed wish for greater evidence  
29  
30 (effectiveness and cost effectiveness) to support more rapid adoption. It was reported that the  
31  
32 escalating uptake of RAS meant that evaluative studies often lagged behind the adoption, an  
33  
34 all too familiar phenomenon in healthcare delivery(11,19,20). There was a perception that  
35  
36 much of the rapid development was somewhat fiscally driven, rather than driven by high  
37  
38 quality evaluative evidence. This imbalance will need addressing, and likely quickly, to help  
39  
40 commissioners make informed decisions about investment in RAS for the longer term.  
41  
42  
43  
44

45 There was a clear perceived need for improved guidance, governance, and regulation. As  
46  
47 articulated by some interviewees, the roll out at present is not supported by a national  
48  
49 framework (in the UK) and, whilst a “light touch” approach can have many positives, it was  
50  
51 clear that a governance framework would help should anything “go wrong”. The safety  
52  
53 reassurance offered at present, especially from a central governance perspective, was not seen  
54  
55 to be effective enough.  
56  
57  
58  
59

60 The surgical training aspect was another area of comment, especially from the trainee group.

1  
2  
3 Achieving competence and experience of RAS using RAS platforms is very different to  
4 standard surgical training. There are currently capacity issues which limit opportunities to train  
5 on RAS systems – especially as the entire workforce requires training. Also, as with other  
6 minimally invasive approaches, becoming accredited in RAS for a procedure may reduce  
7 exposure of a trainee surgeon to non-RAS experience and competence. In contrast, the ability  
8 to quantify expertise and skill was seen as a strong positive feature for RAS. Both for trainees  
9 and experienced surgeons learning a new surgical method, the ability to gauge and grade  
10 competency in a much more quantitative way was welcomed. The need to adapt training to the  
11 changing needs for surgical trainees has been identified in the recent report commissioned by  
12 the Royal college of Surgeons (England)(7).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 There were mixed views on whether centralisation of RAS services should become the model  
28 of choice within the health service. However, there was a strong wish that the way in which  
29 RAS should be rolled out should promote equity of access to treatment. RAS systems are scarce  
30 high value commodities, and currently more difficult to access for some than standard surgery.  
31 Centralisation has been shown to be highly effective for other areas of high-end health care  
32 provision such as specialist major trauma care(21), but this requires further research for the  
33 field of RAS.  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The role of industry figured prominently in the interviews, both positively and sometimes less  
44 so. The main conflict was around perceptions of partiality and market dominance. A  
45 collaborative relationship with an energised and interested industry partner was thought to  
46 bring many benefits (as has been seen with this research project). Training, facilitation,  
47 information sharing and research opportunities/funding were all seen as positive contributions  
48 to RAS development. The perceived influence of industry in the RAS sphere was a concern  
49 voiced by some, especially outside the private sector. However, even in the limited time since  
50 data collection for this report, significant improvements have occurred with industry bodies  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 providing a strong and united voice through institutions such as the Association of British  
4 HealthTech Industries (ABHI) and support of independent research.  
5  
6  
7

8 There is a clear need for wider education amongst the public. The public often perceive RAS  
9 in a potentially disproportionately positive manner, often naively equating advanced  
10 technology (RAS or otherwise) with superior care – there is an assumption that because it is  
11 new, it is automatically good. Public focus group members also found it difficult to discern the  
12 levels of autonomy involved with RAS. Some respondents assumed a lack of surgeon input,  
13 highlighting misconceptions of current RAS systems where the surgeon remains in total control  
14 of both movement and decision making. The “trust” in the surgeon is, and remains, paramount.  
15 Future positioning of RAS, in terms of autonomy and technical hierarchy, and good  
16 descriptions of these for public education, are required. Platforms which aim to inform patients  
17 and public, such as Healthtalk.org, may be useful in this regard.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Strengths and limitations**

32  
33  
34  
35 Strengths of the study included the level of engagement and representation from a significant  
36 body of RAS related experts and personnel, including open and deep insights gained from  
37 industry and hospital managers. There were some limitations to the study. The sample for  
38 interview comprised mostly of surgeons: - the lack of variation of roles within this sample  
39 could be regarded as a limitation. There were dedicated focus groups to ensure surgical trainees  
40 and public perspectives were also represented but the surgeon voice was prevalent. We  
41 attempted to sample multiple specialties to counter criticisms of other qualitative studies which  
42 only focus on a single specialty(22). We also aimed to recruit multiple stakeholders.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 Although we deliberately invited interviewees that were both known to be more or less  
55 positive about RAS for balance, the natural sampling resulted in a preponderance of persons  
56 who were RAS supporters. This is worthy of further comment. The identification of any  
57  
58  
59  
60

1  
2  
3 potential issues and problems with RAS outlined in this study has originated from those who  
4 are, in general, users of RAS and largely supportive, and who have substantial direct insight.  
5  
6 As such, by amplifying the elements of RAS implementation that they have deemed to work  
7  
8 well and by addressing early the elements that they believe still require refinement will likely  
9  
10 head off any more troublesome aspects around future development. Sharing these insights and  
11  
12 thoughts will further this ambition and allow the best possible environment for appropriate roll  
13  
14 out of RAS.  
15  
16  
17  
18  
19

## 20 **Conclusions**

21  
22  
23 Our study demonstrated a largely positive attitude towards the introduction of RAS and an  
24  
25 expectation of continued rapid roll out. It highlighted a range of issues which stakeholders  
26  
27 perceive to be particularly pertinent to the provision of RAS which require greater attention.  
28  
29 These included issues of governance, workforce training, organisation delivery and a  
30  
31 continuing need for public education. These provide useful areas of focus for healthcare  
32  
33 managers and surgeons currently planning the adoption or future expansion of RAS services.  
34  
35  
36  
37  
38  
39

40 \*\* \*\* \*

41  
42  
43  
44  
45  
46 **Acknowledgements:** We thank the participants for their time, energy, and invaluable insight  
47  
48 to assist this research. Thanks to Clare Robertson for facilitating the public focus group.  
49

50  
51 **Contributors:** MKC, DB and KG conceived the study. LL, DB, MKC, KG, and LD undertook  
52  
53 data collection. LL, LD and KG conducted the data analysis. LL, DB, MKC, KG and LD  
54  
55 interpreted the data. LL, DB and MKC drafted the manuscript and circulated to authors for  
56  
57  
58  
59  
60

1  
2  
3 contribution. LL, KG, LD, JT, JM, RK, AI, MKC and DB edited drafts and approved the  
4  
5 current manuscript for publication.  
6  
7

8 **Funding:** This work was supported by Intuitive Surgical (European Research Board) via an  
9  
10 unrestricted grant. The funder had no role in the conception, design, conduct, analysis, or  
11  
12 interpretation of the study.  
13  
14

15  
16 **Competing interests:** None declared.  
17  
18

19 **Patient consent for publication:** Not applicable.  
20  
21

22 **Ethics approval:** This study was approved by the Life Sciences and Medicine Ethics Review  
23  
24 Board (CERB) at the University of Aberdeen (CERB/2020/7/1984). Verbal informed consent  
25  
26 was obtained from all participants.  
27  
28

29 **Data availability statement:** No additional data available.  
30  
31

## 32 33 34 35 36 **REFERENCES** 37 38

- 39 1. Mcleod IK, Melder PC. Da Vinci robot-assisted excision of a vallecular cyst: A case  
40  
41 report. *ENT-Ear, Nose & Throat Journal*. 2005;170–2.  
42  
43
- 44 2. Moawad GN, Rahman S, Martino MA, Klebanoff JS. Robotic surgery during the  
45  
46 COVID pandemic: why now and why for the future. *Journal of Robotic Surgery*. 2020  
47  
48 Dec 1;14(6):917–20.  
49  
50
- 51 3. Ng ATL, Tam PC. Current status of robot-assisted surgery. Vol. 20, *Hong Kong*  
52  
53 *Medical Journal*. Hong Kong Academy of Medicine Press; 2014. p. 241–50.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 4. Matsuyama T, Kinugasa Y, Nakajima Y, Kojima K. Robotic-assisted surgery for rectal  
4 cancer: Current state and future perspective. Vol. 2, *Annals of Gastroenterological*  
5  
6 *Surgery*. Wiley-Blackwell Publishing Ltd; 2018. p. 406–12.  
7
- 8  
9  
10 5. Chan F. Robotic-assisted surgical procedures are the future of gynaecology in  
11  
12 *Australasia*. *Australian and New Zealand Journal of Obstetrics and Gynaecology*.  
13  
14 2018 Jun 1;58(3):371–4.  
15
- 16  
17 6. Brodie A, Vasdev N. The future of robotic surgery. *Ann R Coll Surg Engl*. 2018 Sep  
18  
19 1;100:4–13.  
20
- 21  
22 7. Royal College of Surgeons. Future of Surgery [Internet]. [cited 2021 Jun 1]. Available  
23  
24 from: [futureofsurgery.rcseng.ac.uk](http://futureofsurgery.rcseng.ac.uk)  
25
- 26  
27 8. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering  
28  
29 implementation of health services research findings into practice: A consolidated  
30  
31 framework for advancing implementation science. *Implementation Science*. 2009;4(1).  
32  
33
- 34  
35 9. Arroyo NA, Gessert T, Hitchcock M, Tao M, Smith CD, Greenberg C, et al. What  
36  
37 Promotes Surgeon Practice Change? A Scoping Review of Innovation Adoption in  
38  
39 Surgical Practice. Vol. 273, *Annals of surgery*. NLM (Medline); 2021. p. 474–82.  
40  
41  
42
- 43  
44 10. Rogers EM. Diffusion of innovations. New York: NY: The Free Press; 1995.  
45
- 46  
47 11. Paul S, McCulloch P, Sedrakyan A. Robotic surgery: Revisiting “no innovation  
48  
49 without evaluation.” Vol. 346, *BMJ (Online)*. 2013.  
50
- 51  
52 12. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research  
53  
54 (COREQ): a 32-item checklist for interviews and focus groups. *International Journal*  
55  
56 *for Quality in Health Care*. 2007 Sep 16;19(6):349–57.  
57  
58  
59  
60

- 1  
2  
3 13. Lawrie L, Gillies K, Duncan E, Davies L, Beard. D, Campbell M. Barriers and  
4  
5 enablers to the effective implementation of robotic assisted surgery. Vol. 17, *PLOS*  
6  
7 *ONE*. 2022.  
8  
9
- 10  
11 14. Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What  
12  
13 is an adequate sample size? Operationalising data saturation for theory-based interview  
14  
15 studies. *Psychology and Health*,. 2010.  
16  
17
- 18  
19 15. Microsoft Corporation. Microsoft Teams. Redmond, Washington : One Microsoft  
20  
21 Way.  
22  
23
- 24  
25 16. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in*  
26  
27 *Psychology*. 2006;3(2):77–101.  
28
- 29  
30 17. Jackson K, Bazeley P. Qualitative Data Analysis with NVivo. 3rd Edition. Sage  
31  
32 Publications; 2019.  
33
- 34  
35 18. Microsoft Corporation. Microsoft Excel. Redmond, Washington.  
36
- 37  
38 19. Collins R. Comment Metal-on-metal failures-in science, regulation, and policy. The  
39  
40 Lancet [Internet]. 2012;379:1174–6. Available from: [http://www.ukbiobank.ac.uk/wp-](http://www.ukbiobank.ac.uk/wp-content)  
41  
42 content.  
43  
44
- 45  
46 20. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al.  
47  
48 No surgical innovation without evaluation: the IDEAL recommendations. Vol. 374,  
49  
50 *The Lancet*. Elsevier B.V.; 2009. p. 1105–12.  
51
- 52  
53 21. Metcalfe D, Bouamra O, Parsons NR, Aletrari MO, Lecky FE, Costa ML. Effect of  
54  
55 regional trauma centralization on volume, injury severity and outcomes of injured  
56  
57 patients admitted to trauma centres. *British Journal of Surgery*. 2014;101(8):959–64.  
58  
59  
60




- 1  
2  
3 22. Randell R, Honey S, Hindmarsh J, Alvarado N, Greenhalgh J, Pearman A, et al. A  
4 realist process evaluation of robot-assisted surgery: integration into routine practice  
5 and impacts on communication, collaboration and decision-making. *Health Services*  
6 *and Delivery Research*. 2017 Jun;5(20):1–140.  
7  
8  
9  
10  
11  
12  
13  
14  
15

16 **FIGURE TITLE**

17  
18  
19 **Figure 1. Summary of the key themes arising from the interview and focus group data**  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





## Interview topic guide

Thank you for agreeing to participate in this interview. The general aim of the study is to help us understand more about the uptake of RAS. We are interested to hear what you think are the barriers and facilitators to introducing/scaling up RAS in the NHS and what issues are important to you in relation to RAS services. I have a number of questions I'm going to ask you – some questions may be more relevant to you depending on your role. We are interested in your experiences and views so there are no right or wrong answers. All information collected will be strictly confidential. Our chat today will be recorded. The audio recordings will only be used for transcribing and analysing data.

How does that sound?

Do you have any questions for me before we start?

Do I have your consent to get started?

Before we begin talking specifically about RAS, I would like to get some background information about yourself:

**What is your age?**

**Please indicate your gender.**

**What is your ethnicity?**

Question (background Qs designed to elicit RAS experience to date)	Probe(s)
1. What is your current role?	
2. Can you please start by explaining how familiar you are with RAS and your current level of expertise on the topic?	At what point did you or your team decide to use RAS and for what reason? [CFIR Planning <sup>1</sup> ] [if they have experience] How many years of experience do you have with (using) RAS? [surgeons] How many RAS procedures have you conducted?
3. [If no experience to date]: Do you wish to adopt RAS?	Why or why not?

<sup>1</sup> Consolidated Framework for Implementation Research (CFIR)  
Version 1.0 23/07/2020

## Interview topic guide

4. [If no experience to date]: Have you experienced any issues with the uptake of RAS in the past?		What happened?
<b>Target framework domain/construct</b>	<b>Question (specific Qs related to perspectives of RAS)</b>	<b>Probe(s)</b>
CFIR Evidence of strength and quality, TDF <sup>2</sup> Knowledge	5. Can you comment on the evidence related to RAS?	Evidence from your own research? Practice guidelines? Published literature? Co-workers? Other settings? What do you think of the evidence?
TDF Skills	6. What range of skills do you think are required to deliver RAS effectively?	Both in terms of technical skills to deliver RAS but also leadership, management, tendency towards innovation, agility  What type of training would be helpful?
TDF Beliefs about Consequences	7. In your opinion, what are the benefits of delivering RAS within the NHS?	To yourself, to the patients, colleagues, healthcare organisation, NHS – positive and negative, long/short-term. What about the benefits of not delivering RAS?
TDF Beliefs about Consequences	8. What are the drawbacks of introducing RAS in the NHS?	To yourself, to the patients, colleagues, healthcare organisation, NHS – positive and negative, long/short-term. What about the drawbacks of not introducing RAS to your organisation?
TDF Intentions and Goals, CFIR Other Personal Attributes	9. Can you describe what motivators are there for you personally in delivering RAS?	Has this changed since the introduction of RAS? If yes, what changed your motivation?

<sup>2</sup> Theoretical Domains Framework



## Interview topic guide

CFIR – relative advantage, TDF Goals	10. To what extent do you think that RAS should be a priority for the NHS at the moment?	
CFIR Tension for change, Patient needs and resources	11. Do you think it is really important to have a RAS service in your hospital? Why?	Is it worth it in terms of typical patient demographics, resources required?
TDF Environmental Context and Resources, CFIR Intervention Source, CFIR Structural Characteristics	<p>12. [If RAS already implemented] Again, talking about your specific hospital, has it been relatively easy or difficult to implement RAS? Why?</p> <p>13. [If not implemented already] What is it about your hospital that would make it easier or more difficult to implement RAS in your hospital?</p> <p>14. How does your role/standing in the hospital influence how easy it is/would be to implement RAS?</p>	Resource issues, organisational regulations, equipment, colleagues, the infrastructure of your organisation - social architecture (e.g. roles, hierarchy), age, maturity, size, or physical layout – how does this affect (or will affect) the provision of RAS?
CFIR External Policies and Incentives	<p>[If RAS already implemented]</p> <p>15. Have any external policies or recommendations influenced the decision to implement RAS locally?</p>	Give examples
CFIR Culture, TDF Social Influences, CFIR Peer Pressure,	16. To what extent have the views of others or what you have seen happening in other hospitals affect your uptake of RAS?	Do you think their opinions (would) influence the uptake of RAS? How do you think your organisation's culture (general beliefs, values, assumptions that people embrace) will affect (or does affect) the provision of RAS? Can



### Interview topic guide

<p>CFIR Readiness for Implementation – Leadership Engagement</p>	<p>17. Thinking of other hospitals, in your view, who are the winners and who are the losers in the uptake of RAS?</p> <p>18. How open is your hospital to introducing new innovations like RAS?</p>	<p>you describe an example that highlights this? Example: any generational differences in opinions of RAS? Has this affected your views of RAS?</p>
<p>CFIR Patient Needs &amp; Resources/Peer Pressure</p>	<p>19. How do you think patients will (or do) respond to the introduction of RAS in your hospital?</p>	<p>Do you know how patients have responded to RAS in the past? Do you think RAS meets their needs? Have you heard stories about the experiences of patients who have undergone RAS? (from own hospital or other). Can you describe a specific story? Has this influenced your opinion of RAS?</p>
<p>CFIR Cost</p>	<p>20. How do you think the cost associated with RAS systems affects the use/uptake of it?</p>	
<p>TDF Social Professional Role &amp; Identity</p>	<p>21. Do you think the delivery of RAS should be a standard part of your professional role?</p> <p>22. Do you think the wider uptake of RAS would change the nature of your role?</p>	<p>If yes, in what way? How do you feel about this?</p>
<p>TDF Memory, Attention and Decision Making</p> <p>TDF Environmental Context and Resources</p>	<p>23. Do you think RAS will change how you work? What about for the rest of the surgical team?</p> <p>24. [theatre staff] Do you think RAS changes your situation awareness in the operating room? How does this impact on decision making?</p>	<p>Changes in physical demands of surgery or mental demands (task complexity – link to question about communication requirements).</p> <p>Physical layout changes in the operating room, how do you think this would influence communication? How do you think RAS might change/does change the workflow within the operating theatre?</p>



## Interview topic guide

		<p>Do you think these changes, in workload, (potentially) brought about by RAS would be/are applicable across specialities?</p> <p>Situation awareness – probe: Changes in visual and tactile feedback available to you – what impact does RAS have on this? How do you think this might affect patient outcomes?</p>
TDF Emotions	25. How do you feel about having RAS in your centre? Do you think it affects your credibility? Does it make you feel good? Does it provoke fear? Does it give you concerns?	Are you apprehensive, confident, excited? Why do you feel that way?
<b>Target framework domain/construct</b>	<b>Question (perceptions on the future direction of RAS)</b>	<b>Probe(s)</b>
TDF Optimism	26. What do you think the future of RAS will look like?	Overall, do you expect RAS to be used (more frequently) in the future? Why?
CFIR Tension for change	27. Do you see a need for implementing RAS more widely, outside of your organisation? E.g. should there be a robot in every hospital?	
TDF Beliefs about Consequences	28. What potential concerns, if any, does the future of RAS raise for you? [that we haven't covered already]	
TDF Environmental Context and Resources	29. How do you think NHS circumstances, e.g. in terms of set up and response to COVID, might influence the provision of RAS in the future?	



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Interview topic guide**

TDF Goals, CFIR Relative Advantage	30. In your view, where does investing in RAS sit in the hierarchy of developments that you think are required to improve surgery for the next decade?	
CFIR Complexity	31. Last question! What in your view would be required to move RAS from being in the nice-to-have bracket to the must-have? Is this level of change achievable? Is the effort worth it in your view?	

**Any other issue you would like to raise?**

**Thank you for your time [reassure about confidentiality and contact information if any questions].**

er review only



## COREQ (CONsolidated criteria for REporting Qualitative research) Checklist

A checklist of items that should be included in reports of qualitative research. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Topic	Item No.	Guide Questions/Description	Reported on Page No.
<b>Domain 1: Research team and reflexivity</b>			
<i>Personal characteristics</i>			
Interviewer/facilitator	1	Which author/s conducted the interview or focus group?	
Credentials	2	What were the researcher's credentials? E.g. PhD, MD	
Occupation	3	What was their occupation at the time of the study?	
Gender	4	Was the researcher male or female?	
Experience and training	5	What experience or training did the researcher have?	
<i>Relationship with participants</i>			
Relationship established	6	Was a relationship established prior to study commencement?	
Participant knowledge of the interviewer	7	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	
Interviewer characteristics	8	What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topic	
<b>Domain 2: Study design</b>			
<i>Theoretical framework</i>			
Methodological orientation and Theory	9	What methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis	
<i>Participant selection</i>			
Sampling	10	How were participants selected? e.g. purposive, convenience, consecutive, snowball	
Method of approach	11	How were participants approached? e.g. face-to-face, telephone, mail, email	
Sample size	12	How many participants were in the study?	
Non-participation	13	How many people refused to participate or dropped out? Reasons?	
<i>Setting</i>			
Setting of data collection	14	Where was the data collected? e.g. home, clinic, workplace	
Presence of non-participants	15	Was anyone else present besides the participants and researchers?	
Description of sample	16	What are the important characteristics of the sample? e.g. demographic data, date	
<i>Data collection</i>			
Interview guide	17	Were questions, prompts, guides provided by the authors? Was it pilot tested?	
Repeat interviews	18	Were repeat interviews carried out? If yes, how many?	
Audio/visual recording	19	Did the research use audio or visual recording to collect the data?	
Field notes	20	Were field notes made during and/or after the interview or focus group?	
Duration	21	What was the duration of the interviews or focus group?	
Data saturation	22	Was data saturation discussed?	
Transcripts returned	23	Were transcripts returned to participants for comment and/or	

Topic	Item No.	Guide Questions/Description	Reported on Page No.
		correction?	
<b>Domain 3: analysis and findings</b>			
<i>Data analysis</i>			
Number of data coders	24	How many data coders coded the data?	
Description of the coding tree	25	Did authors provide a description of the coding tree?	
Derivation of themes	26	Were themes identified in advance or derived from the data?	
Software	27	What software, if applicable, was used to manage the data?	
Participant checking	28	Did participants provide feedback on the findings?	
<i>Reporting</i>			
Quotations presented	29	Were participant quotations presented to illustrate the themes/findings? Was each quotation identified? e.g. participant number	
Data and findings consistent	30	Was there consistency between the data presented and the findings?	
Clarity of major themes	31	Were major themes clearly presented in the findings?	
Clarity of minor themes	32	Is there a description of diverse cases or discussion of minor themes?	

Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*. 2007. Volume 19, Number 6: pp. 349 – 357

**Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.**